

Dag Aarsland

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/628921/publications.pdf>

Version: 2024-02-01

571
papers

54,478
citations

1701

104
h-index

1751

212
g-index

630
all docs

630
docs citations

630
times ranked

35727
citing authors

#	ARTICLE	IF	CITATIONS
1	Regression-based norms for the FAS phonemic fluency test for ages 40–84 based on a Norwegian sample. <i>Applied Neuropsychology Adult</i> , 2023, 30, 159-168.	0.7	6
2	Self-harm and Suicidality Experiences of Middle-Age and Older Adults With vs. Without High Autistic Traits. <i>Journal of Autism and Developmental Disorders</i> , 2023, 53, 3034-3046.	1.7	3
3	A 3D deep learning model to predict the diagnosis of dementia with Lewy bodies, Alzheimer's disease, and mild cognitive impairment using brain 18F-FDG PET. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 563-584.	3.3	41
4	Muscle Volume and Intramuscular Fat of the Tongue Evaluated With MRI Predict Malnutrition in People Living With Dementia: A 5-Year Follow-up Study. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2022, 77, 228-234.	1.7	6
5	Genetic evaluation of dementia with Lewy bodies implicates distinct disease subgroups. <i>Brain</i> , 2022, 145, 1757-1762.	3.7	17
6	Elevation of inactive cleaved annexin A1 in the neocortex is associated with amyloid, inflammatory and apoptotic markers in neurodegenerative dementias. <i>Neurochemistry International</i> , 2022, 152, 105251.	1.9	8
7	Risky drinking and cognitive impairment in community residents aged 50 and over. <i>Aging and Mental Health</i> , 2022, 26, 2432-2439.	1.5	4
8	Association of Plasma p-tau181 and p-tau231 Concentrations With Cognitive Decline in Patients With Probable Dementia With Lewy Bodies. <i>JAMA Neurology</i> , 2022, 79, 32.	4.5	38
9	The neuropsychiatry of Parkinson's disease: advances and challenges. <i>Lancet Neurology</i> , The, 2022, 21, 89-102.	4.9	142
10	Psychosis in Alzheimer disease – mechanisms, genetics and therapeutic opportunities. <i>Nature Reviews Neurology</i> , 2022, 18, 131-144.	4.9	62
11	Visual hallucinations in Lewy body disease: pathophysiological insights from phenomenology. <i>Journal of Neurology</i> , 2022, 269, 3636-3652.	1.8	8
12	Prevalence Estimates of Amyloid Abnormality Across the Alzheimer Disease Clinical Spectrum. <i>JAMA Neurology</i> , 2022, 79, 228.	4.5	97
13	Latent subtypes of manic and/or irritable episode symptoms in two population-based cohorts. <i>British Journal of Psychiatry</i> , 2022, 221, 722-731.	1.7	4
14	Traumatic life experiences and post-traumatic stress symptoms in middle-aged and older adults with and without autistic traits. <i>International Journal of Geriatric Psychiatry</i> , 2022, 37, .	1.3	10
15	Parsing heterogeneity within dementia with Lewy bodies using clustering of biological, clinical, and demographic data. <i>Alzheimer's Research and Therapy</i> , 2022, 14, 14.	3.0	10
16	Tongue muscle mass is associated with total grey matter and hippocampal volumes in Dementia with Lewy Bodies. <i>Archives of Gerontology and Geriatrics</i> , 2022, 100, 104647.	1.4	2
17	Actions to be taken for improving functional prognosis in dementia. <i>Journal of the Neurological Sciences</i> , 2022, 434, 120156.	0.3	0
18	Latent subtypes of manic and/or irritable episode symptoms in two population-based cohorts – ERRATUM. <i>British Journal of Psychiatry</i> , 2022, , 1-2.	1.7	0

#	ARTICLE	IF	CITATIONS
19	Neuropsychiatric Symptoms in Dementia: Considering a Clinical Role for Electroencephalography. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2022, 34, 214-223.	0.9	1
20	Timed Up and Go in People with Subjective Cognitive Decline Is Associated with Faster Cognitive Deterioration and Cortical Thickness. <i>Dementia and Geriatric Cognitive Disorders</i> , 2022, 51, 63-72.	0.7	2
21	Reactivity of posterior cortical electroencephalographic alpha rhythms during eyes opening in cognitively intact older adults and patients with dementia due to Alzheimer's and Lewy body diseases. <i>Neurobiology of Aging</i> , 2022, 115, 88-108.	1.5	11
22	Light, sleep-wake rhythm, and behavioural and psychological symptoms of dementia in care home patients: Revisiting the sundowning syndrome. <i>International Journal of Geriatric Psychiatry</i> , 2022, 37, .	1.3	6
23	New insights into the genetic etiology of Alzheimer's disease and related dementias. <i>Nature Genetics</i> , 2022, 54, 412-436.	9.4	700
24	Specific depressive symptoms are related with different patterns of alcohol use in community-dwelling older adults. <i>Archives of Gerontology and Geriatrics</i> , 2022, 101, 104696.	1.4	2
25	Prodromal Dementia With Lewy Bodies and Recurrent Panic Attacks as the First Symptom: A Case Report. <i>Frontiers in Neurology</i> , 2022, 13, 839539.	1.1	6
26	Plasma Neurofilament Light and p-tau181 and Risk of Psychosis in Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2022, , 1-12.	1.5	2
27	Clinical outcome measures in dementia with Lewy bodies trials: critique and recommendations. <i>Translational Neurodegeneration</i> , 2022, 11, 24.	3.6	6
28	Body mass index trajectories and associations with cognitive decline in people with Lewy body dementia and Alzheimer's disease. <i>Health Science Reports</i> , 2022, 5, e590.	0.6	2
29	Are subtypes of affective symptoms differentially associated with change in cognition over time: A latent class analysis. <i>Journal of Affective Disorders</i> , 2022, 309, 437-445.	2.0	5
30	Frailty in Parkinson's disease and its association with early dementia: A longitudinal study. <i>Parkinsonism and Related Disorders</i> , 2022, 99, 51-57.	1.1	5
31	Gender/Sex Differences in the Association of Mild Behavioral Impairment with Cognitive Aging. <i>Journal of Alzheimer's Disease</i> , 2022, 88, 345-355.	1.2	19
32	Protocol for Rhapsody: a longitudinal observational study examining the feasibility of speech phenotyping for remote assessment of neurodegenerative and psychiatric disorders. <i>BMJ Open</i> , 2022, 12, e061193.	0.8	5
33	Using Polygenic Hazard Scores to Predict Age at Onset of Alzheimer's Disease in Nordic Populations. <i>Journal of Alzheimer's Disease</i> , 2022, 88, 1533-1544.	1.2	3
34	The Mental and Physical Health Profiles of Older Adults Who Endorse Elevated Autistic Traits. <i>Journals of Gerontology - Series B Psychological Sciences and Social Sciences</i> , 2021, 76, 1726-1737.	2.4	11
35	The Truth behind the Zeros: A New Approach to Principal Component Analysis of the Neuropsychiatric Inventory. <i>Multivariate Behavioral Research</i> , 2021, 56, 70-85.	1.8	7
36	Antipsychotic use in dementia: the relationship between neuropsychiatric symptom profiles and adverse outcomes. <i>European Journal of Epidemiology</i> , 2021, 36, 89-101.	2.5	26

#	ARTICLE	IF	CITATIONS
37	The association between aspects of carer distress and time until nursing home admission in persons with Alzheimer's disease and dementia with Lewy bodies. <i>International Psychogeriatrics</i> , 2021, 33, 337-345.	0.6	10
38	Next-Generation RNA-Sequencing of Serum Small Extracellular Vesicles Discovers Potential Diagnostic Biomarkers for Dementia With Lewy Bodies. <i>American Journal of Geriatric Psychiatry</i> , 2021, 29, 573-584.	0.6	13
39	Clinical Non-Motor Phenotyping of Black and Asian Minority Ethnic Compared to White Individuals with Parkinson's Disease Living in the United Kingdom. <i>Journal of Parkinson's Disease</i> , 2021, 11, 299-307.	1.5	15
40	Mild Cognitive Impairment: the Manchester consensus. <i>Age and Ageing</i> , 2021, 50, 72-80.	0.7	80
41	Motor signs in Alzheimer's disease and vascular dementia: Detection through natural language processing, co-morbid features and relationship to adverse outcomes. <i>Experimental Gerontology</i> , 2021, 146, 111223.	1.2	4
42	Brain amyloid and vascular risk are related to distinct white matter hyperintensity patterns. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2021, 41, 1162-1174.	2.4	37
43	An international, randomized, placebo-controlled, phase 2b clinical trial of intepirdine for dementia with Lewy bodies (HEADWAY-DLB). <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2021, 7, e12171.	1.8	9
44	Genetic risk for Alzheimer's disease, cognition, and mild behavioral impairment in healthy older adults. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2021, 13, e12164.	1.2	32
45	Dementia with Lewy bodies research consortia: A global perspective from the ISTAART Lewy Body Dementias Professional Interest Area working group. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2021, 13, e12235.	1.2	6
46	Benzodiazepines and antidepressants: Effects on cognitive and functional decline in Alzheimer's disease and Lewy body dementia. <i>International Journal of Geriatric Psychiatry</i> , 2021, 36, 917-925.	1.3	21
47	Association of Malnutrition with Functional and Cognitive Trajectories in People Living with Dementia: A Five-Year Follow-Up Study. <i>Journal of Alzheimer's Disease</i> , 2021, 79, 1713-1722.	1.2	16
48	Associations among education, age, and the dementia with Lewy bodies (DLB) metabolic pattern: A European-DLB consortium project. <i>Alzheimer's and Dementia</i> , 2021, 17, 1277-1286.	0.4	5
49	Genome sequencing analysis identifies new loci associated with Lewy body dementia and provides insights into its genetic architecture. <i>Nature Genetics</i> , 2021, 53, 294-303.	9.4	198
50	Resting-state EEG alpha/theta ratio related to neuropsychological test performance in Parkinson's Disease. <i>Clinical Neurophysiology</i> , 2021, 132, 756-764.	0.7	24
51	Body mass index, performance on activities of daily living and cognition: analysis in two different populations. <i>BMC Geriatrics</i> , 2021, 21, 177.	1.1	12
52	Presynaptic accumulation of α -synuclein causes synaptopathy and progressive neurodegeneration in <i>Drosophila</i> . <i>Brain Communications</i> , 2021, 3, fcab049.	1.5	9
53	Nonmotor symptom burden grading as predictor of cognitive impairment in Parkinson's disease. <i>Brain and Behavior</i> , 2021, 11, e02086.	1.0	6
54	Remote monitoring technologies in Alzheimer's disease: design of the RADAR-AD study. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 89.	3.0	28

#	ARTICLE	IF	CITATIONS
55	A meta-analysis of randomised controlled trials of physical activity in people with Alzheimer's disease and mild cognitive impairment with a comparison to donepezil. <i>International Journal of Geriatric Psychiatry</i> , 2021, 36, 1471-1487.	1.3	19
56	Common variants in Alzheimer's disease and risk stratification by polygenic risk scores. <i>Nature Communications</i> , 2021, 12, 3417.	5.8	140
57	Genome-wide association identifies the first risk loci for psychosis in Alzheimer disease. <i>Molecular Psychiatry</i> , 2021, 26, 5797-5811.	4.1	30
58	A multicentre validation study of the diagnostic value of plasma neurofilament light. <i>Nature Communications</i> , 2021, 12, 3400.	5.8	219
59	Association Between Amygdala Volume and Trajectories of Neuropsychiatric Symptoms in Alzheimer's Disease and Dementia With Lewy Bodies. <i>Frontiers in Neurology</i> , 2021, 12, 679984.	1.1	8
60	Parkinson disease-associated cognitive impairment. <i>Nature Reviews Disease Primers</i> , 2021, 7, 47.	18.1	391
61	Validity and Cultural Generalisability of a 5-Minute AI-Based, Computerised Cognitive Assessment in Mild Cognitive Impairment and Alzheimer's Dementia. <i>Frontiers in Psychiatry</i> , 2021, 12, 706695.	1.3	25
62	Plasma Neurofilament Light Chain Predicts Cognitive Progression in Prodromal and Clinical Dementia with Lewy Bodies. <i>Journal of Alzheimer's Disease</i> , 2021, 82, 913-919.	1.2	27
63	Serum tyrosine is associated with better cognition in Lewy body dementia. <i>Brain Research</i> , 2021, 1765, 147481.	1.1	9
64	Neuropsychiatric symptoms and brain morphology in patients with mild cognitive impairment and Alzheimer's disease with dementia. <i>International Psychogeriatrics</i> , 2021, 33, 1217-1228.	0.6	20
65	Constipation is Associated with Development of Cognitive Impairment in de novo Parkinson's Disease: A Longitudinal Analysis of Two International Cohorts. <i>Journal of Parkinson's Disease</i> , 2021, 11, 1209-1219.	1.5	29
66	Assessing Genetic Overlap and Causality Between Blood Plasma Proteins and Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2021, 83, 1825-1839.	1.2	5
67	Subjective Cognitive and Communicative Complaints and Health-Related Quality of Life in Parkinson's Disease with and without Mild Cognitive Impairment. <i>Revista Colombiana De Psiquiatria</i> , 2021, , .	0.1	0
68	A genome-wide association study with 1,126,563 individuals identifies new risk loci for Alzheimer's disease. <i>Nature Genetics</i> , 2021, 53, 1276-1282.	9.4	430
69	Polypharmacy is associated with functional decline in Alzheimer's disease and Lewy body dementia. <i>Archives of Gerontology and Geriatrics</i> , 2021, 96, 104459.	1.4	12
70	Cerebrovascular disease, neurodegeneration, and clinical phenotype in dementia with Lewy bodies. <i>Neurobiology of Aging</i> , 2021, 105, 252-261.	1.5	18
71	A genome-wide association study of plasma phosphorylated tau181. <i>Neurobiology of Aging</i> , 2021, 106, 304.e1-304.e3.	1.5	5
72	Differentiating traits and states identifies the importance of chronic neuropsychiatric symptoms for cognitive prognosis in mild dementia. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2021, 13, e12152.	1.2	3

#	ARTICLE	IF	CITATIONS
73	The diagnostic and prognostic capabilities of plasma biomarkers in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2021, 17, 1145-1156.	0.4	174
74	Loneliness, physical activity, and mental health during COVID-19: a longitudinal analysis of depression and anxiety in adults over the age of 50 between 2015 and 2020. <i>International Psychogeriatrics</i> , 2021, 33, 505-514.	0.6	135
75	Cerebrospinal fluid markers for synaptic function and Alzheimer type changes in late life depression. <i>Scientific Reports</i> , 2021, 11, 20375.	1.6	9
76	Examination of cognitive performance and mild behavioral impairment domains of apathy, mood, impulse dyscontrol, social inappropriateness and psychosis in cognitively normal adults aged 50 and over. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
77	The impact of the COVID-19 pandemic on cognitive health. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	1
78	Long-term cognitive and motor decline across the spectrum of Lewy body disease. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
79	Hypertension, brain training and cognition in the healthy adults aged over 50 years: An online longitudinal study. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
80	Repeated concussions associated with worsened working memory, attention and processing speed, but preserved delayed memory: A PROTECT study. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
81	A remote digital tool for diagnosis and monitoring of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	1
82	Self and informant-rated mild behavioral impairment and genetic risk for AD: The respondent matters. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	1
83	A randomised placebo-controlled study on the effects of anthocyanins for maintaining cognitive functioning in individuals at increased risk for dementia. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
84	Associations between amygdala volume and trajectories of neuropsychiatric symptoms in Alzheimer's disease and dementia with Lewy Bodies. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
85	Augmented reality to detect subtle alterations in the early stages of Alzheimer's disease: Preliminary results of the RADAR-AD study. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	1
86	Gait characteristics in preclinical Alzheimer's disease: Preliminary results of the RADAR-AD study. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	1
87	Mediating effect of mutuality on caregiver burden in Parkinson's disease partners. <i>Aging and Mental Health</i> , 2020, 24, 1421-1428.	1.5	21
88	Profile of mild behavioral impairment and factor structure of the Mild Behavioral Impairment Checklist in cognitively normal older adults. <i>International Psychogeriatrics</i> , 2020, 32, 705-717.	0.6	57
89	CSF tau proteins correlate with an atypical clinical presentation in dementia with Lewy bodies. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 109-110.	0.9	8
90	Postmortem Cortical Transcriptomics of Lewy Body Dementia Reveal Mitochondrial Dysfunction and Lack of Neuroinflammation. <i>American Journal of Geriatric Psychiatry</i> , 2020, 28, 75-86.	0.6	38

#	ARTICLE	IF	CITATIONS
91	The individual course of neuropsychiatric symptoms in people with Alzheimer's and Lewy body dementia: 12-year longitudinal cohort study. <i>British Journal of Psychiatry</i> , 2020, 216, 43-48.	1.7	54
92	Drug and Disease Effects in Parkinson's Psychosis: Revisiting the Role of Dopamine. <i>Movement Disorders Clinical Practice</i> , 2020, 7, 32-36.	0.8	13
93	Components of the choline oxidation pathway modify the association between the apolipoprotein ϵ 4 gene variant and cognitive decline in patients with dementia. <i>Brain Research</i> , 2020, 1726, 146519.	1.1	3
94	Greater Variability in Cognitive Decline in Lewy Body Dementia Compared to Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2020, 73, 1321-1330.	1.2	9
95	Metabolic Correlates of Dopaminergic Loss in Dementia with Lewy Bodies. <i>Movement Disorders</i> , 2020, 35, 595-605.	2.2	42
96	β -Amyloid and tau biomarkers and clinical phenotype in dementia with Lewy bodies. <i>Neurology</i> , 2020, 95, e3257-e3268.	1.5	62
97	Hippocampal subfields and decline in activities of daily living in Alzheimer's disease and dementia with Lewy bodies. <i>Neurodegenerative Disease Management</i> , 2020, 10, 357-367.	1.2	4
98	Psychosis in Alzheimer's Disease. <i>Current Neurology and Neuroscience Reports</i> , 2020, 20, 57.	2.0	28
99	The combined effect of amyloid- β and tau biomarkers on brain atrophy in dementia with Lewy bodies. <i>NeuroImage: Clinical</i> , 2020, 27, 102333.	1.4	22
100	Are neuropsychiatric symptoms in dementia linked to CSF biomarkers of synaptic and axonal degeneration?. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 153.	3.0	9
101	Selecting Remote Measurement Technologies to Optimize Assessment of Function in Early Alzheimer's Disease: A Case Study. <i>Frontiers in Psychiatry</i> , 2020, 11, 582207.	1.3	17
102	Systems Biology Approaches to Understand the Host-Microbiome Interactions in Neurodegenerative Diseases. <i>Frontiers in Neuroscience</i> , 2020, 14, 716.	1.4	39
103	Psychiatric and neuropsychiatric syndromes and COVID-19. <i>Lancet Psychiatry</i> , 2020, 7, 663-664.	3.7	5
104	Plasma p-tau181 accurately predicts Alzheimer's disease pathology at least 8 years prior to post-mortem and improves the clinical characterisation of cognitive decline. <i>Acta Neuropathologica</i> , 2020, 140, 267-278.	3.9	209
105	An epigenome-wide association study of Alzheimer's disease blood highlights robust DNA hypermethylation in the HOXB6 gene. <i>Neurobiology of Aging</i> , 2020, 95, 26-45.	1.5	51
106	Neuropsychiatric Symptoms and Functional Decline in Alzheimer's Disease and Lewy Body Dementia. <i>Journal of the American Geriatrics Society</i> , 2020, 68, 2257-2263.	1.3	21
107	Integrated lipidomics and proteomics network analysis highlights lipid and immunity pathways associated with Alzheimer's disease. <i>Translational Neurodegeneration</i> , 2020, 9, 36.	3.6	37
108	Effects of Purified Anthocyanins in People at Risk for Dementia: Study Protocol for a Phase II Randomized Controlled Trial. <i>Frontiers in Neurology</i> , 2020, 11, 916.	1.1	8

#	ARTICLE	IF	CITATIONS
109	Implementing Remote Memory Clinics to Enhance Clinical Care During and After COVID-19. <i>Frontiers in Psychiatry</i> , 2020, 11, 579934.	1.3	44
110	Drug repositioning and repurposing for Alzheimer disease. <i>Nature Reviews Neurology</i> , 2020, 16, 661-673.	4.9	97
111	Increased Cerebrospinal Fluid Concentration of ZnT3 Is Associated with Cognitive Impairment in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2020, 77, 1143-1155.	1.2	13
112	Trajectories of depressive symptoms and associated patterns of cognitive decline. <i>Scientific Reports</i> , 2020, 10, 20888.	1.6	35
113	A Preliminary Investigation of the Views of People With Parkinson's (With and Without Psychosis) and Caregivers on Participating in Clinical Trials During the Covid-19 Pandemic: An Online Survey. <i>Frontiers in Psychiatry</i> , 2020, 11, 602480.	1.3	1
114	Cleaved Annexin A1 is elevated in neurodegenerative dementia and is associated with pathological burden of amyloid and inflammatory cytokines. <i>Alzheimer's and Dementia</i> , 2020, 16, e037636.	0.4	1
115	Linking electronic dementia care records to national inpatient data in dementia with Lewy bodies: Frequency, duration and cost implications of hospitalization and recording of delirium episodes. <i>Alzheimer's and Dementia</i> , 2020, 16, e039139.	0.4	1
116	Antipsychotic use in dementia: The relationship between neuropsychiatric symptom profiles and adverse outcomes. <i>Alzheimer's and Dementia</i> , 2020, 16, e039145.	0.4	0
117	Clinical factors associated with progression to dementia in people with late-life depression: A cohort study of patients in secondary care. <i>Alzheimer's and Dementia</i> , 2020, 16, e039147.	0.4	1
118	Decreased JNK3 levels are associated with amyloid plaque and neurofibrillary tangles in dementia patients. <i>Alzheimer's and Dementia</i> , 2020, 16, e039231.	0.4	0
119	Ultrasensitive blood biomarkers to predict cognitive decline and diagnose Alzheimer's disease in the absence of AT(N) classification as the reference standard. <i>Alzheimer's and Dementia</i> , 2020, 16, e041808.	0.4	1
120	Neuropsychiatric symptoms correlated with functional trajectories among people living with Alzheimer's disease dementia and Lewy body dementia. <i>Alzheimer's and Dementia</i> , 2020, 16, e041881.	0.4	0
121	The ANeED study: Ambroxol in new and early dementia with Lewy bodies. <i>Alzheimer's and Dementia</i> , 2020, 16, e042589.	0.4	2
122	A systematic review on the physical and mental health risk factors of mild cognitive impairment and Alzheimer's disease in military veterans. <i>Alzheimer's and Dementia</i> , 2020, 16, e042913.	0.4	0
123	Data-assisted differential diagnosis of dementia by deep neural networks using MRI: A study from the European DLB consortium. <i>Alzheimer's and Dementia</i> , 2020, 16, e043593.	0.4	1
124	A prospective long-term study of TDP43 pathology in Alzheimer's disease aggression. <i>Alzheimer's and Dementia</i> , 2020, 16, e043659.	0.4	0
125	Neuropsychiatric symptoms and cognitive decline: Trait or state effects?. <i>Alzheimer's and Dementia</i> , 2020, 16, e043789.	0.4	0
126	Functional alterations in visual networks underlie differences in the phenomenology of visual hallucinations in Lewy body disease. <i>Alzheimer's and Dementia</i> , 2020, 16, e045102.	0.4	0

#	ARTICLE	IF	CITATIONS
127	Different abnormalities of electroencephalographic (EEG) markers in quiet wakefulness are related to motor visual hallucinations in patients with Parkinson's and Lewy body diseases. <i>Alzheimer's and Dementia</i> , 2020, 16, e045811.	0.4	0
128	Different abnormalities of electroencephalographic (EEG) markers in quiet wakefulness are related to visual hallucinations in patients with Parkinson's and Lewy body diseases. <i>Alzheimer's and Dementia</i> , 2020, 16, e045886.	0.4	1
129	Plasma-based biomarkers for A β and tau predict longitudinal brain atrophy in cognitively healthy elderly and in patients with Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2020, 16, e046490.	0.4	0
130	Plasma p-tau181 accurately predicts Alzheimer's disease pathology at least 8 years prior to post-mortem and improves the clinical characterisation of cognitive decline. <i>Alzheimer's and Dementia</i> , 2020, 16, e047539.	0.4	2
131	The reliability of a deep learning model in external memory clinic MRI data: A multi-cohort study. <i>Alzheimer's and Dementia</i> , 2020, 16, e042969.	0.4	0
132	FLAME: A computerized neuropsychological composite for trials in early dementia. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2020, 12, e12098.	1.2	13
133	Urinary metabolic phenotyping for Alzheimer's disease. <i>Scientific Reports</i> , 2020, 10, 21745.	1.6	30
134	The reliability of a deep learning model in clinical out-of-distribution MRI data: A multicohort study. <i>Medical Image Analysis</i> , 2020, 66, 101714.	7.0	90
135	Mental health of people living with dementia in care homes during COVID-19 pandemic. <i>International Psychogeriatrics</i> , 2020, 32, 1253-1254.	0.6	48
136	Clinical factors associated with progression to dementia in people with late-life depression: a cohort study of patients in secondary care. <i>BMJ Open</i> , 2020, 10, e035147.	0.8	10
137	Abnormal cortical neural synchronization mechanisms in quiet wakefulness are related to motor deficits, cognitive symptoms, and visual hallucinations in Parkinson's disease patients: an electroencephalographic study. <i>Neurobiology of Aging</i> , 2020, 91, 88-111.	1.5	24
138	Temporal Relationship Between Depressive Symptoms and Cognition in Mid and Late Life: A Longitudinal Cohort Study. <i>Journal of the American Medical Directors Association</i> , 2020, 21, 1108-1113.	1.2	18
139	Lemur Tyrosine Kinase 2 (LMTK2) Level Inversely Correlates with Phospho-Tau in Neuropathological Stages of Alzheimer's Disease. <i>Brain Sciences</i> , 2020, 10, 68.	1.1	5
140	Colombian consortium for the study of Lewy body dementia COL-DLB. <i>Journal of the Neurological Sciences</i> , 2020, 412, 116807.	0.3	2
141	Risk of Hospitalization in Patients with Alzheimer's Disease and Lewy Body Dementia: Time to and Length of Stay. <i>Journal of Alzheimer's Disease</i> , 2020, 74, 1221-1230.	1.2	4
142	An update on blood-based biomarkers for non-Alzheimer neurodegenerative disorders. <i>Nature Reviews Neurology</i> , 2020, 16, 265-284.	4.9	121
143	Neuropsychiatric symptoms and cognitive abilities over the initial quinquennium of Parkinson disease. <i>Annals of Clinical and Translational Neurology</i> , 2020, 7, 449-461.	1.7	44
144	Neuronal surface autoantibodies in dementia: a systematic review and meta-analysis. <i>Journal of Neurology</i> , 2020, 268, 2769-2779.	1.8	19

#	ARTICLE	IF	CITATIONS
145	Association between physical activity and cognition in Mexican and Korean older adults. Archives of Gerontology and Geriatrics, 2020, 89, 104047.	1.4	9
146	Research criteria for the diagnosis of prodromal dementia with Lewy bodies. Neurology, 2020, 94, 743-755.	1.5	365
147	The Mental and Physical Health of Older Adults With a Genetic Predisposition for Autism. Autism Research, 2020, 13, 641-654.	2.1	7
148	Adult Hippocampal Neurogenesis in Major Depressive Disorder and Alzheimer's Disease. Trends in Molecular Medicine, 2020, 26, 803-818.	3.5	98
149	Exploration of Plasma Lipids in Mild Cognitive Impairment due to Alzheimer's Disease. Journal of Alzheimer's Disease, 2020, 77, 1117-1127.	1.2	5
150	Improving mental health and reducing antipsychotic use in people with dementia in care homes: the WHELD research programme including two RCTs. Programme Grants for Applied Research, 2020, 8, 1-98.	0.4	15
151	Predictive and diagnostic utility of brief neuropsychological assessment in detecting Alzheimer's pathology and progression to dementia.. Neuropsychology, 2020, 34, 851-861.	1.0	5
152	Lysosomal cathepsin D is upregulated in Alzheimer's disease neocortex and may be a marker for neurofibrillary degeneration. Brain Pathology, 2019, 29, 63-74.	2.1	48
153	Advanced cerebral amyloid angiopathy and small vessel disease are associated with psychosis in Alzheimer's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 728-730.	0.9	19
154	Effects of Anthocyanin Supplementation on Serum Lipids, Glucose, Markers of Inflammation and Cognition in Adults With Increased Risk of Dementia – A Pilot Study. Frontiers in Genetics, 2019, 10, 536.	1.1	14
155	Examining the association between genetic liability for schizophrenia and psychotic symptoms in Alzheimer's disease. Translational Psychiatry, 2019, 9, 273.	2.4	36
156	Kynurenines, Neuropsychiatric Symptoms, and Cognitive Prognosis in Patients with Mild Dementia. International Journal of Tryptophan Research, 2019, 12, 117864691987788.	1.0	13
157	Increased plasma neurofilament light chain concentration correlates with severity of post-mortem neurofibrillary tangle pathology and neurodegeneration. Acta Neuropathologica Communications, 2019, 7, 5.	2.4	125
158	European DLB consortium: diagnostic and prognostic biomarkers in dementia with Lewy bodies, a multicenter international initiative. Neurodegenerative Disease Management, 2019, 9, 247-250.	1.2	18
159	Mild Behavioral Impairment as a Marker of Cognitive Decline in Cognitively Normal Older Adults. American Journal of Geriatric Psychiatry, 2019, 27, 823-834.	0.6	144
160	Prevalence of late-life depression and gap in mental health service use across European regions. European Psychiatry, 2019, 57, 19-25.	0.1	103
161	Frailty in Older Adults with Mild Dementia: Dementia with Lewy Bodies and Alzheimer's Disease. Dementia and Geriatric Cognitive Disorders Extra, 2019, 9, 176-183.	0.6	28
162	GBA and APOE ε4 associate with sporadic dementia with Lewy bodies in European genome wide association study. Scientific Reports, 2019, 9, 7013.	1.6	53

#	ARTICLE	IF	CITATIONS
163	Cortical thinning in patients with REM sleep behavior disorder is associated with clinical progression. <i>Npj Parkinson's Disease</i> , 2019, 5, 7.	2.5	40
164	The association between specific neuropsychiatric disturbances in people with Alzheimer's disease and dementia with Lewy bodies and carer distress. <i>International Journal of Geriatric Psychiatry</i> , 2019, 34, 1421-1428.	1.3	12
165	Combinatory microRNA serum signatures as classifiers of Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2019, 64, 202-210.	1.1	27
166	Association of depressive symptoms and subjective memory complaints with the incidence of cognitive impairment in older adults with high blood pressure. <i>European Geriatric Medicine</i> , 2019, 10, 413-420.	1.2	17
167	Glial activation and inflammation along the Alzheimer's disease continuum. <i>Journal of Neuroinflammation</i> , 2019, 16, 46.	3.1	175
168	Serum Potassium Is Associated with Cognitive Decline in Patients with Lewy Body Dementia. <i>Journal of Alzheimer's Disease</i> , 2019, 68, 239-253.	1.2	1
169	Metabolic patterns across core features in dementia with lewy bodies. <i>Annals of Neurology</i> , 2019, 85, 715-725.	2.8	47
170	Novel Treatment Opportunities Against Cognitive Impairment in Parkinson's Disease with an Emphasis on Diabetes-Related Pathways. <i>CNS Drugs</i> , 2019, 33, 143-160.	2.7	21
171	A plasma protein classifier for predicting amyloid burden for preclinical Alzheimer's disease. <i>Science Advances</i> , 2019, 5, eaau7220.	4.7	59
172	Comparison of clinical and neuropathological diagnoses of neurodegenerative diseases in two centres from the Brains for Dementia Research (BDR) cohort. <i>Journal of Neural Transmission</i> , 2019, 126, 327-337.	1.4	33
173	Clinical Presentation, Diagnostic Features, and Mortality in Dementia with Lewy Bodies. <i>Journal of Alzheimer's Disease</i> , 2019, 67, 995-1005.	1.2	16
174	The relationship between the frequency of number puzzle use and baseline cognitive function in a large online sample of adults aged 50 and over. <i>International Journal of Geriatric Psychiatry</i> , 2019, 34, 932-940.	1.3	10
175	Neuropathological characterization of Lemur tyrosine kinase 2 (LMTK2) in Alzheimer's disease and neocortical Lewy body disease. <i>Scientific Reports</i> , 2019, 9, 17222.	1.6	12
176	Commentary: A posterior-to-anterior shift of brain functional dynamics in aging. <i>Frontiers in Aging Neuroscience</i> , 2019, 11, 341.	1.7	2
177	The Associations Between Cognitive Prognosis and Kynurenines Are Modified by the Apolipoprotein ϵ 4 Allele Variant in Patients With Dementia. <i>International Journal of Tryptophan Research</i> , 2019, 12, 117864691988563.	1.0	1
178	The Incidence of Recorded Delirium Episodes Before and After Dementia Diagnosis: Differences Between Dementia With Lewy Bodies and Alzheimer's Disease. <i>Journal of the American Medical Directors Association</i> , 2019, 20, 604-609.	1.2	22
179	A signature pattern of cortical atrophy in dementia with Lewy bodies: A study on 333 patients from the European DLB consortium. <i>Alzheimer's and Dementia</i> , 2019, 15, 400-409.	0.4	60
180	Survival time and differences between dementia with Lewy bodies and Alzheimer's disease following diagnosis: A meta-analysis of longitudinal studies. <i>Ageing Research Reviews</i> , 2019, 50, 72-80.	5.0	70

#	ARTICLE	IF	CITATIONS
181	Genome-wide meta-analysis identifies new loci and functional pathways influencing Alzheimer's disease risk. <i>Nature Genetics</i> , 2019, 51, 404-413.	9.4	1,625
182	The Effect of a Multicomponent Intervention on Quality of Life in Residents of Nursing Homes: A Randomized Controlled Trial (COSMOS). <i>Journal of the American Medical Directors Association</i> , 2019, 20, 330-339.	1.2	50
183	In Brief Neuropsychological Assessment, Amnesic Mild Cognitive Impairment (MCI) Is associated with Cerebrospinal Fluid Biomarkers for Cognitive Decline in Contrast to the Prevailing NIA-AA MCI Criterion. <i>Journal of Alzheimer's Disease</i> , 2019, 67, 715-723.	1.2	5
184	Amyloid- β^2 and Parkinson's disease. <i>Journal of Neurology</i> , 2019, 266, 2605-2619.	1.8	79
185	Investigating the relationship between age of onset of depressive disorder and cognitive function. <i>International Journal of Geriatric Psychiatry</i> , 2019, 34, 38-46.	1.3	26
186	Reduced Walking Speed in Subjective and Mild Cognitive Impairment: A Cross-Sectional Study. <i>Journal of Geriatric Physical Therapy</i> , 2019, 42, E122-E128.	0.6	29
187	Abnormalities of Resting State Cortical EEG Rhythms in Subjects with Mild Cognitive Impairment Due to Alzheimer's and Lewy Body Diseases. <i>Journal of Alzheimer's Disease</i> , 2018, 62, 247-268.	1.2	50
188	Risk factors for non-motor symptoms in Parkinson's disease. <i>Lancet Neurology</i> , The, 2018, 17, 559-568.	4.9	225
189	Patterns of carer distress over time in mild dementia. <i>International Journal of Geriatric Psychiatry</i> , 2018, 33, 987-993.	1.3	12
190	Strengths and challenges in conducting clinical trials in Parkinson's disease mild cognitive impairment. <i>Movement Disorders</i> , 2018, 33, 520-527.	2.2	14
191	Biomarkers for cognitive impairment in Lewy body disorders: Status and relevance for clinical trials. <i>Movement Disorders</i> , 2018, 33, 528-536.	2.2	17
192	Hospitalization in people with dementia with Lewy bodies: Frequency, duration, and cost implications. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2018, 10, 143-152.	1.2	44
193	Abnormalities of resting-state functional cortical connectivity in patients with dementia due to Alzheimer's and Lewy body diseases: an EEG study. <i>Neurobiology of Aging</i> , 2018, 65, 18-40.	1.5	61
194	Synaptic markers of cognitive decline in neurodegenerative diseases: a proteomic approach. <i>Brain</i> , 2018, 141, 582-595.	3.7	172
195	Prevalence of the apolipoprotein E ϵ^4 allele in amyloid β^2 positive subjects across the spectrum of Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2018, 14, 913-924.	0.4	58
196	Glucocerebrosidase mutations and neuropsychiatric phenotypes in Parkinson's disease and Lewy body dementias: Review and meta-analyses. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2018, 177, 232-241.	1.1	49
197	Systematic review of the efficacy of non-pharmacological interventions in people with Lewy body dementia. <i>International Psychogeriatrics</i> , 2018, 30, 395-407.	0.6	35
198	Association of Cerebral Amyloid- β^2 Aggregation With Cognitive Functioning in Persons Without Dementia. <i>JAMA Psychiatry</i> , 2018, 75, 84.	6.0	133

#	ARTICLE	IF	CITATIONS
199	Montreal Cognitive Assessment in a 63- to 65-year-old Norwegian Cohort from the General Population: Data from the Akershus Cardiac Examination 1950 Study. <i>Dementia and Geriatric Cognitive Disorders Extra</i> , 2018, 7, 318-327.	0.6	17
200	P3â€²43: THE ASSOCIATION OF LONGITUDINAL PLASMA NFL WITH POSTMORTEM NEUROPATHOLOGY. <i>Alzheimer's and Dementia</i> , 2018, 14, P1165.	0.4	0
201	P3â€²54: PROFILE OF MILD BEHAVIOURAL IMPAIRMENT IN A POPULATIONâ€²BASED SAMPLE OF ADULTS AGED 50 AND OVER: INITIAL FINDINGS FROM THE PROTECT STUDY. <i>Alzheimer's and Dementia</i> , 2018, 14, P1335.	0.4	2
202	P1â€²523: THE RELATIONSHIP BETWEEN THE MILD BEHAVIOURAL IMPAIRMENT CHECKLIST (MBIâ€²) TOTAL SCORE AND CORE ASPECTS OF COGNITIVE FUNCTION IN OLDER ADULTS. <i>Alzheimer's and Dementia</i> , 2018, 14, P532.	0.4	0
203	P1â€²151: GENETIC OVERLAP BETWEEN PSYCHOTIC SYMPTOMS ACROSS THE LIFESPAN: FINDINGS FROM SCHIZOPHRENIA, COGNITIVELY NORMAL OLDER ADULTS AND ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2018, 14, P335.	0.4	0
204	P2â€²483: DEPRESSION IS ASSOCIATED WITH IMPAIRMENT IN COGNITIVE FUNCTION IN ADULTS AGED 50 AND OVER. <i>Alzheimer's and Dementia</i> , 2018, 14, P914.	0.4	0
205	P1â€²658: REPEATED COGNITIVE TESTING REDUCES SAMPLE SIZE NECESSARY TO DETECT CLINICALLY RELEVANT EFFECTS. <i>Alzheimer's and Dementia</i> , 2018, 14, P595.	0.4	1
206	O1â€²10â€²04: ABNORMALITIES OF RESTING STATE FUNCTIONAL CORTICAL CONNECTIVITY IN PATIENTS WITH DEMENTIA DUE TO ALZHEIMER'S AND LEWY BODY DISEASES: AN EEG STUDY. <i>Alzheimer's and Dementia</i> , 2018, 14, P244.	0.4	0
207	Meta-analysis of Alzheimerâ€²s disease on 9,751 samples from Norway and IGAP study identifies four risk loci. <i>Scientific Reports</i> , 2018, 8, 18088.	1.6	47
208	Cognitive Interventions in Parkinsonâ€²s Disease: Where We Want to Go within 20 Years. <i>Journal of Parkinson's Disease</i> , 2018, 8, S107-S113.	1.5	19
209	Cerebrospinal fluid neurogranin/Î²â€²site APPâ€²cleaving enzyme 1 predicts cognitive decline in preclinical Alzheimer's disease. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2018, 4, 617-627.	1.8	24
210	Mediating Effect of Mutuality on Health-Related Quality of Life in Patients with Parkinsonâ€²s Disease. <i>Parkinson's Disease</i> , 2018, 2018, 1-8.	0.6	7
211	P3â€²001: A RANDOMIZED, PLACEBOâ€²CONTROLLED TRIAL TO INVESTIGATE SAFETY OF BUPRENORPHINE TRANSDERMAL SYSTEM FOR PAIN MANAGEMENT IN PEOPLE WITH DEMENTIA. <i>Alzheimer's and Dementia</i> , 2018, 14, P1062.	0.4	0
212	Tolerability of buprenorphine transdermal system in nursing home patients with advanced dementia: a randomized, placebo-controlled trial (DEP.PAIN.DEM). <i>Clinical Interventions in Aging</i> , 2018, Volume 13, 935-946.	1.3	35
213	A Longitudinal Study of Neurocognition in Dementia with Lewy Bodies Compared to Alzheimerâ€²s Disease. <i>Frontiers in Neurology</i> , 2018, 9, 124.	1.1	15
214	Course of neuropsychiatric symptoms in dementia: 5â€²year longitudinal study. <i>International Journal of Geriatric Psychiatry</i> , 2018, 33, 1361-1369.	1.3	65
215	Assessment and Management of Neuropsychiatric Symptoms in Parkinsonâ€²s Disease. <i>CNS Drugs</i> , 2018, 32, 621-635.	2.7	43
216	Antibodies to Multiple Receptors are Associated with Neuropsychiatric Symptoms and Mortality in Alzheimerâ€²s Disease: A Longitudinal Study. <i>Journal of Alzheimer's Disease</i> , 2018, 64, 761-774.	1.2	7

#	ARTICLE	IF	CITATIONS
217	Efficacy and Safety of Analgesic Treatment for Depression in People with Advanced Dementia: Randomised, Multicentre, Double-Blind, Placebo-Controlled Trial (DEP.PAIN.DEM). <i>Drugs and Aging</i> , 2018, 35, 545-558.	1.3	22
218	Apathy is associated with faster global cognitive decline and early nursing home admission in dementia with Lewy bodies. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 83.	3.0	17
219	Cognition among individuals along a spectrum of increased risk for Parkinson's disease. <i>PLoS ONE</i> , 2018, 13, e0201964.	1.1	33
220	(-)-Phenserine and Inhibiting Pre-Programmed Cell Death: In Pursuit of a Novel Intervention for Alzheimer's Disease. <i>Current Alzheimer Research</i> , 2018, 15, 883-891.	0.7	15
221	Potentially inappropriate medications and drug-drug interactions in home-dwelling people with mild dementia. <i>International Journal of Geriatric Psychiatry</i> , 2017, 32, 183-192.	1.3	22
222	The psychosis spectrum in Parkinson disease. <i>Nature Reviews Neurology</i> , 2017, 13, 81-95.	4.9	252
223	Effect of Vascular Risk Factors on the Progression of Mild Alzheimer's Disease and Lewy Body Dementia. <i>Journal of Alzheimer's Disease</i> , 2017, 56, 575-584.	1.2	18
224	SpotLight Proteomics: uncovering the hidden blood proteome improves diagnostic power of proteomics. <i>Scientific Reports</i> , 2017, 7, 41929.	1.6	27
225	Reduction of RPT6/S8 (a Proteasome Component) and Proteasome Activity in the Cortex is Associated with Cognitive Impairment in Lewy Body Dementia. <i>Journal of Alzheimer's Disease</i> , 2017, 57, 373-386.	1.2	14
226	Cognitive decline in Parkinson disease. <i>Nature Reviews Neurology</i> , 2017, 13, 217-231.	4.9	705
227	Lewy Body Dementias. <i>Focus (American Psychiatric Publishing)</i> , 2017, 15, 85-100.	0.4	2
228	Abnormalities of cortical neural synchronization mechanisms in patients with dementia due to Alzheimer's and Lewy body diseases: an EEG study. <i>Neurobiology of Aging</i> , 2017, 55, 143-158.	1.5	76
229	Associations between pain and depression in nursing home patients at different stages of dementia. <i>Journal of Affective Disorders</i> , 2017, 218, 8-14.	2.0	39
230	A new tool to identify patients with Parkinson's disease at increased risk of dementia. <i>Lancet Neurology</i> , The, 2017, 16, 576-578.	4.9	7
231	Psychosis in Parkinson's Disease. <i>International Review of Neurobiology</i> , 2017, 133, 585-622.	0.9	30
232	Diagnosis and management of dementia with Lewy bodies. <i>Neurology</i> , 2017, 89, 88-100.	1.5	2,805
233	Novel evidence associates higher plasma α -synuclein levels and cognitive impairment in Parkinson's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017, 88, 808-808.	0.9	7
234	Effects of Risperidone and Galantamine Treatment on Alzheimer's Disease Biomarker Levels in Cerebrospinal Fluid. <i>Journal of Alzheimer's Disease</i> , 2017, 57, 387-393.	1.2	11

#	ARTICLE	IF	CITATIONS
235	Long-Term Cognitive Decline in Dementia with Lewy Bodies in a Large Multicenter, International Cohort. <i>Journal of Alzheimer's Disease</i> , 2017, 57, 787-795.	1.2	69
236	The relationship of specific items on the Neuropsychiatric Inventory to caregiver burden in dementia: a systematic review. <i>International Journal of Geriatric Psychiatry</i> , 2017, 32, 703-717.	1.3	91
237	Risk factors for early psychosis in PD: insights from the Parkinson's Progression Markers Initiative. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017, 88, 325-331.	0.9	78
238	The prognosis of dementia with Lewy bodies. <i>Lancet Neurology</i> , The, 2017, 16, 390-398.	4.9	159
239	Increased Transforming Growth Factor β 2 in the Neocortex of Alzheimer's Disease and Dementia with Lewy Bodies is Correlated with Disease Severity and Soluble A β 42 Load. <i>Journal of Alzheimer's Disease</i> , 2017, 56, 157-166.	1.2	25
240	Cognitive Deficits in Chronic Stroke Patients: Neuropsychological Assessment, Depression, and Self-Reports. <i>Dementia and Geriatric Cognitive Disorders Extra</i> , 2017, 7, 283-296.	0.6	42
241	Abnormalities of Cortical Neural Synchronization Mechanisms in Subjects with Mild Cognitive Impairment due to Alzheimer's and Parkinson's Diseases: An EEG Study. <i>Journal of Alzheimer's Disease</i> , 2017, 59, 339-358.	1.2	45
242	[P3-017]: HEADWAY-DB: A MULTINATIONAL STUDY EVALUATING THE SAFETY AND EFFICACY OF INTEPIRIDINE (RVT-101) IN DEMENTIA WITH LEWY BODIES. <i>Alzheimer's and Dementia</i> , 2017, 13, P936.	0.4	4
243	Fourteen sequence variants that associate with multiple sclerosis discovered by meta-analysis informed by genetic correlations. <i>Npj Genomic Medicine</i> , 2017, 2, 24.	1.7	16
244	Impaired synaptic function is linked to cognition in Parkinson's disease. <i>Annals of Clinical and Translational Neurology</i> , 2017, 4, 700-713.	1.7	23
245	Cerebrospinal Fluid Biomarkers of Cognitive Decline in Parkinson's Disease. <i>International Review of Neurobiology</i> , 2017, 132, 275-294.	0.9	34
246	Synaptic proteins in CSF relate to Parkinson's disease stage markers. <i>Npj Parkinson's Disease</i> , 2017, 3, 7.	2.5	49
247	Psychometric properties of the mutuality scale in Swedish dyads with Parkinson's disease. <i>Acta Neurologica Scandinavica</i> , 2017, 136, 122-128.	1.0	11
248	Classifying Alzheimer's disease, Lewy body dementia, and normal controls using 3D texture analysis in magnetic resonance images. <i>Biomedical Signal Processing and Control</i> , 2017, 33, 19-29.	3.5	15
249	Importance of Proactive Treatment of Depression in Lewy Body Dementias: The Impact on Hippocampal Neurogenesis and Cognition in a Post-Mortem Study. <i>Dementia and Geriatric Cognitive Disorders</i> , 2017, 44, 283-293.	0.7	14
250	[P1-235]: RELATIONSHIP BETWEEN PATHOLOGY SCORES, CLINICAL DATA AND EXPRESSION LEVELS OF PROTEASOME SUBUNITS IN ALZHEIMER'S DISEASE AND LEWY BODY DEMENTIAS. <i>Alzheimer's and Dementia</i> , 2017, 13, P333.	0.4	0
251	[P3-243]: A MASS SPECTROMETRY-BASED DISCOVERY AND REPLICATION OF A MULTI-ANALYTE CLASSIFIER FOR NEOCORTICAL AMYLOID PATHOLOGY. <i>Alzheimer's and Dementia</i> , 2017, 13, P1033.	0.4	0
252	[P4-154]: DETECTING AT-RISK CASES FOR ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2017, 13, P13170.	0.4	0

#	ARTICLE	IF	CITATIONS
253	[P1â€“299]: AN EVALUATION OF PREDICTORS AND COGNITIVE DECLINE ASSOCIATED WITH PERSISTENT AND TRANSIENT PSYCHOTIC SYMPTOMS IN ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2017, 13, P367.	0.4	1
254	[P1â€“456]: INCREASED PSER129 Î±â€“SYNUCLEIN IS ASSOCIATED WITH SYNAPTIC DEFICITS IN DEMENTIA WITH LEWY BODIES. <i>Alzheimer's and Dementia</i> , 2017, 13, P461.	0.4	0
255	[P1â€“564]: RISK AND DURATION OF HOSPITALIZATION IN DEMENTIA WITH LEWY BODIES. <i>Alzheimer's and Dementia</i> , 2017, 13, P510.	0.4	1
256	[P2â€“204]: RPT6, 20S Î±â€“6 AND Î±â€“3 PROTEASOME SUBUNIT LEVELS AND ASSOCIATION WITH COGNITIVE DECLINE IN ALZHEIMER'S DISEASE AND LEWY BODY DEMENTIAS. <i>Alzheimer's and Dementia</i> , 2017, 13, P684.	0.4	0
257	[F5â€“01â€“03]: CLINICOâ€“PATHOLOGIC ASSOCIATIONS IN DLB: RELEVANCE FOR DIAGNOSIS AND TREATMENT. <i>Alzheimer's and Dementia</i> , 2017, 13, P1444.	0.4	0
258	Accuracy of Clinical Diagnosis of Dementia with Lewy Bodies versus Neuropathology. <i>Journal of Alzheimer's Disease</i> , 2017, 59, 1139-1152.	1.2	63
259	Screening for Alzheimerâ€™s Disease: Cognitive Impairment in Self-Referred and Memory Clinic-Referred Patients. <i>Journal of Alzheimer's Disease</i> , 2017, 60, 1621-1631.	1.2	8
260	New Therapeutic Strategies for Lewy Body Dementias. <i>Current Neurology and Neuroscience Reports</i> , 2017, 17, 68.	2.0	28
261	MRI-Based Classification Models in Prediction of Mild Cognitive Impairment and Dementia in Late-Life Depression. <i>Frontiers in Aging Neuroscience</i> , 2017, 9, 13.	1.7	73
262	REM Sleep Behavior Disorder Is Not Associated with a More Rapid Cognitive Decline in Mild Dementia. <i>Frontiers in Neurology</i> , 2017, 8, 375.	1.1	8
263	Determinants of Dyadic Relationship and Its Psychosocial Impact in Patients with Parkinsonâ€™s Disease and Their Spouses. <i>Parkinson's Disease</i> , 2017, 2017, 1-9.	0.6	17
264	Detecting At-Risk Alzheimerâ€™s Disease Cases. <i>Journal of Alzheimer's Disease</i> , 2017, 60, 97-105.	1.2	42
265	Antibodies to Signaling Molecules and Receptors in Alzheimerâ€™s Disease are Associated with Psychomotor Slowing, Depression, and Poor Visuospatial Function. <i>Journal of Alzheimer's Disease</i> , 2017, 59, 929-939.	1.2	15
266	Multiple modality biomarker prediction of cognitive impairment in prospectively followed de novo Parkinson disease. <i>PLoS ONE</i> , 2017, 12, e0175674.	1.1	110
267	The Lewy Body Dementias: Dementia with Lewy Bodies and Related Syndromes. , 2017, , 211-224.		0
268	Decreased Levels of VAMP2 and Monomeric Alpha-Synuclein Correlate with Duration of Dementia. <i>Journal of Alzheimer's Disease</i> , 2016, 50, 101-110.	1.2	24
269	Neuropsychological Profiles in Mild Cognitive Impairment due to Alzheimerâ€™s and Parkinsonâ€™s Diseases. <i>Journal of Parkinson's Disease</i> , 2016, 6, 413-421.	1.5	10
270	Alzheimer's disease cerebrospinal fluid biomarkers predict cognitive decline in lewy body dementia. <i>Movement Disorders</i> , 2016, 31, 1203-1208.	2.2	70

#	ARTICLE	IF	CITATIONS
271	Unfolded protein response is activated in Lewy body dementias. <i>Neuropathology and Applied Neurobiology</i> , 2016, 42, 352-365.	1.8	41
272	Muscarinic M1 Receptor Coupling to G-protein is Intact in Parkinson's Disease Dementia. <i>Journal of Parkinson's Disease</i> , 2016, 6, 733-739.	1.5	3
273	Cognitive decline in dementia with Lewy bodies: a 5-year prospective cohort study. <i>BMJ Open</i> , 2016, 6, e010357.	0.8	57
274	Association of Butyrylcholinesterase-K Allele and Apolipoprotein E ε4 Allele with Cognitive Decline in Dementia with Lewy Bodies and Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2016, 50, 567-576.	1.2	15
275	EEG Markers of Dementia with Lewy Bodies: A Multicenter Cohort Study. <i>Journal of Alzheimer's Disease</i> , 2016, 54, 1649-1657.	1.2	47
276	03402: Clinico-Pathologic Correlations in Dementia with Lewy Bodies (DLB): A Prospective Cohort Study. <i>Alzheimer's and Dementia</i> , 2016, 12, P291.	0.4	0
277	Neurocognitive Deficits Distinguishing Mild Dementia with Lewy Bodies from Mild Alzheimer's Disease are Associated with Parkinsonism. <i>Journal of Alzheimer's Disease</i> , 2016, 53, 1277-1285.	1.2	17
278	Synaptic proteins predict cognitive decline in Alzheimer's disease and Lewy body dementia. <i>Alzheimer's and Dementia</i> , 2016, 12, 1149-1158.	0.4	126
279	Antipsychotic Drug Use Is Not Associated With Long-Term Mortality Risk in Norwegian Nursing Home Patients. <i>Journal of the American Medical Directors Association</i> , 2016, 17, 464.e1-464.e7.	1.2	14
280	Antidepressants and mortality risk in a dementia cohort: data from SveDem, the Swedish Dementia Registry. <i>Acta Psychiatrica Scandinavica</i> , 2016, 134, 430-440.	2.2	32
281	Increased phosphorylation of collapsin response mediator protein-2 at Thr514 correlates with β-amyloid burden and synaptic deficits in Lewy body dementias. <i>Molecular Brain</i> , 2016, 9, 84.	1.3	26
282	Non-Alzheimer Dementias. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2016, 29, 247-248.	1.2	0
283	Signs of Imminent Dying and Change in Symptom Intensity During Pharmacological Treatment in Dying Nursing Home Patients: A Prospective Trajectory Study. <i>Journal of the American Medical Directors Association</i> , 2016, 17, 821-827.	1.2	22
284	Anthocyanins protect from complex I inhibition and APPswe mutation through modulation of the mitochondrial fission/fusion pathways. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2016, 1862, 2110-2118.	1.8	29
285	Loss of Dopamine Transporter Binding and Clinical Symptoms in Dementia with Lewy Bodies. <i>Movement Disorders</i> , 2016, 31, 118-125.	2.2	29
286	Evolution of clinical features in possible DLB depending on FP-CIT SPECT result. <i>Neurology</i> , 2016, 87, 1045-1051.	1.5	14
287	Cerebrospinal Fluid Alzheimer's Disease Biomarkers Across the Spectrum of Lewy Body Diseases: Results from a Large Multicenter Cohort. <i>Journal of Alzheimer's Disease</i> , 2016, 54, 287-295.	1.2	77
288	Higher Frequency and Complexity of Sleep Disturbances in Dementia with Lewy Bodies as Compared to Alzheimer's Disease. <i>Neurodegenerative Diseases</i> , 2016, 16, 152-160.	0.8	34

#	ARTICLE	IF	CITATIONS
289	Hippocampal subfield atrophy in relation to cerebrospinal fluid biomarkers and cognition in early Parkinson's disease: a cross-sectional study. <i>Npj Parkinson's Disease</i> , 2016, 2, 15030.	2.5	24
290	Association of Platelet Serotonin Levels in Alzheimer's Disease with Clinical and Cerebrospinal Fluid Markers. <i>Journal of Alzheimer's Disease</i> , 2016, 53, 621-630.	1.2	19
291	Pharmacological Modulations of the Serotonergic System in a Cell-Model of Familial Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2016, 53, 349-361.	1.2	9
292	Caregiver burden in family carers of people with dementia with Lewy bodies and Alzheimer's disease. <i>International Journal of Geriatric Psychiatry</i> , 2016, 31, 1075-1083.	1.3	117
293	CAIDE Dementia Risk Score and biomarkers of neurodegeneration in memory clinic patients without dementia. <i>Neurobiology of Aging</i> , 2016, 42, 124-131.	1.5	29
294	A longitudinal study of anxiety and cognitive decline in dementia with Lewy bodies and Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2016, 8, 3.	3.0	42
295	Analgesic prescribing patterns in Norwegian nursing homes from 2000 to 2011: trend analyses of four data samples. <i>Age and Ageing</i> , 2016, 45, 54-60.	0.7	55
296	Biological confounders for the values of cerebrospinal fluid proteins in Parkinson's disease and related disorders. <i>Journal of Neurochemistry</i> , 2016, 139, 290-317.	2.1	58
297	MMSE and MoCA in Parkinson's disease and dementia with Lewy bodies: a multicenter 1-year follow-up study. <i>Journal of Neural Transmission</i> , 2016, 123, 431-438.	1.4	102
298	Cognitive impairment in Parkinson's disease and dementia with Lewy bodies. <i>Parkinsonism and Related Disorders</i> , 2016, 22, S144-S148.	1.1	113
299	Isoelectric point region pI ^{7.4} as a treasure island of abnormal proteoforms in blood. <i>Discoveries</i> , 2016, 4, e67.	1.5	4
300	P2-135: CSF a β 42 is related to cortical metabolism (FDG-PET) in non-demented parkinson's disease patients. , 2015, 11, P536-P537.		0
301	Neuropsychiatric Symptoms in Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2015, 5, 659-667.	1.5	66
302	Harnessing the power of cohort studies for dementia research. <i>Journal of Public Mental Health</i> , 2015, 14, 8-17.	0.8	6
303	Associations between Cerebrospinal Fluid Biomarkers and Cognition in Early Untreated Parkinson's Disease. <i>Journal of Parkinson's Disease</i> , 2015, 5, 783-792.	1.5	37
304	Autoantibodies Toward the Angiotensin 2 Type 1 Receptor: A Novel Autoantibody in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2015, 47, 523-529.	1.2	25
305	Reply to letter to the editor "Independent application of MoCA/MMSE conversion" by Armstrong et al.. <i>Movement Disorders</i> , 2015, 30, 1711-1711.	2.2	0
306	Personality Changes after Deep Brain Stimulation in Parkinson's Disease. <i>Parkinson's Disease</i> , 2015, 2015, 1-7.	0.6	40

#	ARTICLE	IF	CITATIONS
307	Classifying Dementia Using Local Binary Patterns from Different Regions in Magnetic Resonance Images. <i>International Journal of Biomedical Imaging</i> , 2015, 2015, 1-14.	3.0	29
308	COSMOS—improving the quality of life in nursing home patients: protocol for an effectiveness-implementation cluster randomized clinical hybrid trial. <i>Implementation Science</i> , 2015, 10, 131.	2.5	46
309	O5—03—04: Clinical characteristics and course of dlb: Results from a large longitudinal multicentre cohort. <i>Alzheimer's and Dementia</i> , 2015, 11, P320.	0.4	2
310	Clinical and Neuropsychological Differences between Mild Parkinson's Disease Dementia and Dementia with Lewy Bodies. <i>Dementia and Geriatric Cognitive Disorders Extra</i> , 2015, 5, 212-220.	0.6	33
311	Neurobiological correlates of depressive symptoms in people with subjective and mild cognitive impairment. <i>Acta Psychiatrica Scandinavica</i> , 2015, 131, 139-147.	2.2	30
312	A Double-Blind Randomized Placebo-Controlled Withdrawal Trial Comparing Memantine and Antipsychotics for the Long-Term Treatment of Function and Neuropsychiatric Symptoms in People With Alzheimer's Disease (MAIN-AD). <i>Journal of the American Medical Directors Association</i> , 2015, 16, 316-322.	1.2	19
313	Medial Temporal Lobe Atrophy and Depressive Symptoms in Elderly Patients With and Without Alzheimer Disease. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2015, 28, 40-48.	1.2	22
314	Genetic overlap between Alzheimer's disease and Parkinson's disease at the MAPT locus. <i>Molecular Psychiatry</i> , 2015, 20, 1588-1595.	4.1	133
315	5-HT1B and other related serotonergic proteins are altered in APPswe mutation. <i>Neuroscience Letters</i> , 2015, 594, 137-143.	1.0	14
316	Amyloid- β^2 and α -synuclein cerebrospinal fluid biomarkers and cognition in early Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2015, 21, 758-764.	1.1	59
317	Prevalence of Cerebral Amyloid Pathology in Persons Without Dementia. <i>JAMA - Journal of the American Medical Association</i> , 2015, 313, 1924.	3.8	1,166
318	Loss-of-function variants in ABCA7 confer risk of Alzheimer's disease. <i>Nature Genetics</i> , 2015, 47, 445-447.	9.4	283
319	Aberrant cerebral network topology and mild cognitive impairment in early Parkinson's disease. <i>Human Brain Mapping</i> , 2015, 36, 2980-2995.	1.9	87
320	Cognitive performance and neuropsychiatric symptoms in early, untreated Parkinson's disease. <i>Movement Disorders</i> , 2015, 30, 919-927.	2.2	244
321	Polygenic Overlap Between C-Reactive Protein, Plasma Lipids, and Alzheimer Disease. <i>Circulation</i> , 2015, 131, 2061-2069.	1.6	145
322	Lewy body dementias. <i>Lancet, The</i> , 2015, 386, 1683-1697.	6.3	422
323	Neuroanatomical correlates of late-life depression and associated cognitive changes. <i>Neurobiology of Aging</i> , 2015, 36, 3090-3099.	1.5	34
324	Cerebrospinal fluid biomarkers in trials for Alzheimer and Parkinson diseases. <i>Nature Reviews Neurology</i> , 2015, 11, 41-55.	4.9	144

#	ARTICLE	IF	CITATIONS
325	Memantine improves attention and episodic memory in Parkinson's disease dementia and dementia with Lewy bodies. <i>International Journal of Geriatric Psychiatry</i> , 2015, 30, 46-54.	1.3	67
326	Depression and Synaptic Zinc Regulation in Alzheimer Disease, Dementia with Lewy Bodies, and Parkinson Disease Dementia. <i>American Journal of Geriatric Psychiatry</i> , 2015, 23, 141-148.	0.6	38
327	Regional Multiple Pathology Scores Are Associated with Cognitive Decline in <sc>L</sc>ewy Body Dementias. <i>Brain Pathology</i> , 2015, 25, 401-408.	2.1	144
328	Grey Matter Changes in Cognitively Impaired Parkinson's Disease Patients. <i>PLoS ONE</i> , 2014, 9, e85595.	1.1	69
329	Large-scale resting state network correlates of cognitive impairment in Parkinson's disease and related dopaminergic deficits. <i>Frontiers in Systems Neuroscience</i> , 2014, 8, 45.	1.2	90
330	Neuropsychiatric symptoms in dementiaâ€”A role for neuroinflammation?. <i>Brain Research Bulletin</i> , 2014, 108, 88-93.	1.4	44
331	The value of personalized psychosocial interventions to address behavioral and psychological symptoms in people with dementia living in care home settings: a systematic review. <i>International Psychogeriatrics</i> , 2014, 26, 1083-1098.	0.6	134
332	Treatment effect of memantine on survival in dementia with Lewy bodies and Parkinson's disease with dementia: a prospective study. <i>BMJ Open</i> , 2014, 4, e005158-e005158.	0.8	47
333	A systematic review of cognitive decline in dementia with Lewy bodies versus Alzheimerâ€™s disease. <i>Alzheimer's Research and Therapy</i> , 2014, 6, 53.	3.0	21
334	Random Forest ensembles for detection and prediction of Alzheimer's disease with a good between-cohort robustness. <i>NeuroImage: Clinical</i> , 2014, 6, 115-125.	1.4	233
335	Apolipoprotein E Â2 genotype delays onset of dementia with Lewy bodies in a Norwegian cohort. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2014, 85, 1227-1231.	0.9	64
336	White matter integrity and cognition in Parkinson's disease: a cross-sectional study. <i>BMJ Open</i> , 2014, 4, e003976.	0.8	41
337	Influence of age, disease onset and <i>ApoE4</i> on visual medial temporal lobe atrophy cutâ€”offs. <i>Journal of Internal Medicine</i> , 2014, 275, 317-330.	2.7	60
338	Assessment of ZnT3 and PSD95 protein levels in Lewy body dementias and Alzheimer's disease: association with cognitive impairment. <i>Neurobiology of Aging</i> , 2014, 35, 2836-2844.	1.5	94
339	Efficacy of pain treatment on mood syndrome in patients with dementia: a randomized clinical trial. <i>International Journal of Geriatric Psychiatry</i> , 2014, 29, 828-836.	1.3	69
340	Cognitive executive impairment and dopaminergic deficits in <i>de novo</i> Parkinson's disease. <i>Movement Disorders</i> , 2014, 29, 1802-1808.	2.2	66
341	Comorbidity profile in dementia with Lewy bodies versus Alzheimerâ€™s disease: a linkage study between the Swedish Dementia Registry and the Swedish National Patient Registry. <i>Alzheimer's Research and Therapy</i> , 2014, 6, 65.	3.0	32
342	Conversion between Miniâ€”Mental State Examination, Montreal Cognitive Assessment, and Dementia Rating Scaleâ€”2 scores in Parkinson's disease. <i>Movement Disorders</i> , 2014, 29, 1809-1815.	2.2	86

#	ARTICLE	IF	CITATIONS
343	Galantamine versus Risperidone for Agitation in People with Dementia: A Randomized, Twelve-Week, Single-Center Study. <i>Dementia and Geriatric Cognitive Disorders</i> , 2014, 38, 234-244.	0.7	11
344	Long-Term Mortality in a Cohort of Home-Dwelling Elderly with Mild Alzheimer's Disease and Lewy Body Dementia. <i>Dementia and Geriatric Cognitive Disorders</i> , 2014, 38, 161-169.	0.7	50
345	Decreased immunoreactivities of neocortical AMPA receptor subunits correlate with motor disability in Lewy body dementias. <i>Journal of Neural Transmission</i> , 2014, 121, 71-78.	1.4	3
346	Short- and Long-term Mortality Risk Associated with the Use of Antipsychotics Among 26,940 Dementia Outpatients: A Population-Based Study. <i>American Journal of Geriatric Psychiatry</i> , 2014, 22, 321-331.	0.6	64
347	Psychiatric issues in cognitive impairment. <i>Movement Disorders</i> , 2014, 29, 651-662.	2.2	41
348	Time until nursing home admission in people with mild dementia: comparison of dementia with Lewy bodies and Alzheimer's dementia. <i>International Journal of Geriatric Psychiatry</i> , 2014, 29, 392-398.	1.3	79
349	Cortical Changes Associated with Depression and Antidepressant Use in Alzheimer and Lewy Body Dementia: An MRI Surface-based Morphometric Study. <i>American Journal of Geriatric Psychiatry</i> , 2014, 22, 4-13.e1.	0.6	41
350	Impact of a stepwise protocol for treating pain on pain intensity in nursing home patients with dementia: A cluster randomized trial. <i>European Journal of Pain</i> , 2014, 18, 1490-1500.	1.4	74
351	Structural brain changes associated with depressive symptoms in the elderly with Alzheimer's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2014, 85, 930-935.	0.9	53
352	The importance of pain management in older people with dementia. <i>British Medical Bulletin</i> , 2014, 111, 139-148.	2.7	75
353	Determining the Association of the 5HTTLPR Polymorphism with Delusions and Hallucinations in Lewy Body Dementias. <i>American Journal of Geriatric Psychiatry</i> , 2014, 22, 580-586.	0.6	19
354	The cerebrospinal fluid "Alzheimer profile" Easily said, but what does it mean?. <i>Alzheimer's and Dementia</i> , 2014, 10, 713.	0.4	249
355	The Use and Costs of Formal Care in Newly Diagnosed Dementia: A Three-Year Prospective Follow-Up Study. <i>American Journal of Geriatric Psychiatry</i> , 2014, 22, 381-388.	0.6	53
356	Initial cognitive decline is associated with cortical thinning in early Parkinson disease. <i>Neurology</i> , 2014, 82, 2017-2025.	1.5	158
357	The Response of Agitated Behavior to Pain Management in Persons with Dementia. <i>American Journal of Geriatric Psychiatry</i> , 2014, 22, 708-717.	0.6	132
358	Agitation in Dementia: Relation to Core Cerebrospinal Fluid Biomarker Levels. <i>Dementia and Geriatric Cognitive Disorders Extra</i> , 2014, 4, 335-343.	0.6	32
359	Persistence and Prognostic Implications of Orthostatic Hypotension in Older Individuals with Mild-to-Moderate Dementia. <i>Dementia and Geriatric Cognitive Disorders Extra</i> , 2014, 4, 283-296.	0.6	4
360	A 5-YEAR LONGITUDINAL STUDY OF PATIENTS WITH DEMENTIA WITH LEWY BODIES AND ALZHEIMER'S DISEASE. , 2014, 10, P261-P261.		1

#	ARTICLE	IF	CITATIONS
361	The value of personalized psychosocial interventions to address behavioral and psychological symptoms in people with dementia living in care home settings: a systematic review â€“ CORRIGENDUM. <i>International Psychogeriatrics</i> , 2014, 26, 1099-1099.	0.6	3
362	A systematic review of cognitive decline in dementia with Lewy bodies versus Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2014, 6, 53.	3.0	19
363	Dynamin1 concentration in the prefrontal cortex is associated with cognitive impairment in Lewy body dementia. <i>F1000Research</i> , 2014, 3, 108.	0.8	15
364	Multivariate classification of patients with Alzheimer's and dementia with Lewy bodies using high-dimensional cortical thickness measurements: an MRI surface-based morphometric study. <i>Journal of Neurology</i> , 2013, 260, 1104-1115.	1.8	41
365	O3-10-01: Clinical course of Lewy-body disease: Cognitive decline and mortality. , 2013, 9, P537-P538.		1
366	Many roads lead to Parkinson's disease. <i>Movement Disorders</i> , 2013, 28, 122-123.	2.2	3
367	Neuropsychiatric Symptoms in Patients with Dementias Associated with Cortical Lewy Bodies: Pathophysiology, Clinical Features, and Pharmacological Management. <i>Drugs and Aging</i> , 2013, 30, 603-611.	1.3	54
368	Using biomarkers to disentangle different causes of Parkinsonism. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2013, 84, 119-119.	0.9	1
369	(¹²³ I)FP-CIT SPECT in suspected dementia with Lewy bodies: a longitudinal case study. <i>BMJ Open</i> , 2013, 3, e002642.	0.8	26
370	Cerebrospinal fluid amyloid- β and phenotypic heterogeneity in de novo Parkinson's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2013, 84, 537-543.	0.9	56
371	Comparing Clinical Profiles in Alzheimer's Disease and Parkinson's Disease Dementia. <i>Dementia and Geriatric Cognitive Disorders Extra</i> , 2013, 3, 281-290.	0.6	7
372	Impulse control disorders and related behaviors. , 2013, , 140-152.		3
373	Neuropsychiatric and cognitive disorders in other parkinsonian disorders. , 2013, , 261-274.		3
374	Neuropsychiatric aspects of the on/off phenomenon. , 2013, , 275-284.		1
375	Correlates of Subjective and Mild Cognitive Impairment: Depressive Symptoms and CSF Biomarkers. <i>Dementia and Geriatric Cognitive Disorders Extra</i> , 2013, 3, 291-300.	0.6	38
376	Mapping Cortical Atrophy in Parkinson's Disease Patients with Dementia. <i>Journal of Parkinson's Disease</i> , 2013, 3, 69-76.	1.5	38
377	Journal Watch: Our panel of experts highlight the most important research articles across the spectrum of topics relevant to the field of neurodegenerative disease management. <i>Neurodegenerative Disease Management</i> , 2013, 3, 105-107.	1.2	0
378	Diffusion Tensor Imaging Surpasses Cerebrospinal Fluid as Predictor of Cognitive Decline and Medial Temporal Lobe Atrophy in Subjective Cognitive Impairment and Mild Cognitive Impairment. <i>Journal of Alzheimer's Disease</i> , 2013, 33, 723-736.	1.2	95

#	ARTICLE	IF	CITATIONS
379	Demography, diagnostics, and medication in dementia with Lewy bodies and Parkinson's disease with dementia: data from the Swedish Dementia Quality Registry (SveDem). <i>Neuropsychiatric Disease and Treatment</i> , 2013, 9, 927.	1.0	33
380	A Pilot Study Examining Associations between DYRK1A and α -Synuclein Dementias. <i>Neurodegenerative Diseases</i> , 2012, 10, 229-231.	0.8	19
381	Biomarkers for dementia diagnosis: differentiating DLB and FTD may be difficult. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2012, 83, 1037-1037.	0.9	1
382	White Matter Hyperintensities and the Course of Depressive Symptoms in Elderly People with Mild Dementia. <i>Dementia and Geriatric Cognitive Disorders Extra</i> , 2012, 2, 97-111.	0.6	38
383	The frequency and correlates of anxiety in patients with first-time diagnosed mild dementia. <i>International Psychogeriatrics</i> , 2012, 24, 1771-1778.	0.6	43
384	Memantine for dementia in adults older than 40 years with Down's syndrome (MEADOWS): a randomised, double-blind, placebo-controlled trial. <i>Lancet</i> , 2012, 379, 528-536.	6.3	144
385	Cognitive impairment in patients with Parkinson's disease: diagnosis, biomarkers, and treatment. <i>Lancet Neurology</i> , 2012, 11, 697-707.	4.9	432
386	Gender-related differences in the burden of non-motor symptoms in Parkinson's disease. <i>Journal of Neurology</i> , 2012, 259, 1639-1647.	1.8	211
387	No association of COMT val158met polymorphism and psychotic symptoms in Lewy body dementias. <i>Neuroscience Letters</i> , 2012, 531, 1-4.	1.0	7
388	Comparing Hippocampal Atrophy in Alzheimer's Dementia and Dementia with Lewy Bodies. <i>Dementia and Geriatric Cognitive Disorders</i> , 2012, 34, 44-50.	0.7	43
389	Assessment and treatment of pain in people with dementia. <i>Nature Reviews Neurology</i> , 2012, 8, 264-274.	4.9	270
390	Depression in Parkinson disease: epidemiology, mechanisms and management. <i>Nature Reviews Neurology</i> , 2012, 8, 35-47.	4.9	431
391	Multispectral MRI segmentation of age related white matter changes using a cascade of support vector machines. <i>Journal of the Neurological Sciences</i> , 2012, 322, 211-216.	0.3	44
392	The Impact of Autonomic Dysfunction on Survival in Patients with Dementia with Lewy Bodies and Parkinson's Disease with Dementia. <i>PLoS ONE</i> , 2012, 7, e45451.	1.1	107
393	Relationship between Orthostatic Hypotension and White Matter Hyperintensity Load in Older Patients with Mild Dementia. <i>PLoS ONE</i> , 2012, 7, e52196.	1.1	12
394	Cerebrospinal Fluid Alzheimer Markers in Depressed Elderly Subjects with and without Alzheimer's Disease. <i>Dementia and Geriatric Cognitive Disorders Extra</i> , 2012, 2, 48-56.	0.6	42
395	Clinical Trials of Dementia With Lewy Bodies and Parkinson's Disease Dementia. <i>Current Neurology and Neuroscience Reports</i> , 2012, 12, 492-501.	2.0	39
396	Identifying prodromal Parkinson's disease: Pre-motor disorders in Parkinson's disease. <i>Movement Disorders</i> , 2012, 27, 617-626.	2.2	443

#	ARTICLE	IF	CITATIONS
397	Cost-effectiveness of memantine in moderate and severe Alzheimer's disease in Norway. <i>International Journal of Geriatric Psychiatry</i> , 2012, 27, 573-582.	1.3	20
398	Systematic review of services providing information and/or advice to people with dementia and/or their caregivers. <i>International Journal of Geriatric Psychiatry</i> , 2012, 27, 628-636.	1.3	71
399	Neuropsychiatric Symptoms in Mild Dementia with Lewy Bodies and Alzheimer's Disease. <i>Dementia and Geriatric Cognitive Disorders</i> , 2012, 34, 1-6.	0.7	66
400	Diagnostic criteria for mild cognitive impairment in Parkinson's disease: Movement Disorder Society Task Force guidelines. <i>Movement Disorders</i> , 2012, 27, 349-356.	2.2	1,908
401	Optimised Anaesthesia to Reduce Post Operative Cognitive Decline (POCD) in Older Patients Undergoing Elective Surgery, a Randomised Controlled Trial. <i>PLoS ONE</i> , 2012, 7, e37410.	1.1	201
402	Parkinson's disease dementia and dementia with Lewy bodies – epidemiology, risk factors and biomarkers. <i>Norsk Epidemiologi</i> , 2012, 22, .	0.2	2
403	Developing predictive biomarkers for dementia of Parkinson's disease. <i>Expert Review of Neurotherapeutics</i> , 2011, 11, 1661-1663.	1.4	0
404	Efficacy of treating pain to reduce behavioural disturbances in residents of nursing homes with dementia: cluster randomised clinical trial. <i>BMJ: British Medical Journal</i> , 2011, 343, d4065-d4065.	2.4	461
405	Quality of Life and the Effect of Memantine in Dementia with Lewy Bodies and Parkinson's Disease Dementia. <i>Dementia and Geriatric Cognitive Disorders</i> , 2011, 32, 227-234.	0.7	44
406	A Novel Blood Test for the Early Detection of Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2011, 23, 121-129.	1.2	71
407	Cognitive and psychiatric disturbances in Parkinson's disease. <i>Aging Health</i> , 2011, 7, 123-142.	0.3	6
408	Dementia associated with Parkinson's disease: Applying the Movement Disorder Society Task Force criteria. <i>Parkinsonism and Related Disorders</i> , 2011, 17, 621-624.	1.1	61
409	Executive Dysfunction in Mild Cognitive Impairment is Associated with Changes in Frontal and Cingulate White Matter Tracts. <i>Journal of Alzheimer's Disease</i> , 2011, 27, 453-462.	1.2	58
410	Effects of Cholinesterase Inhibitors in Parkinson's Disease Dementia: A Review of Clinical Data. <i>CNS Neuroscience and Therapeutics</i> , 2011, 17, 428-441.	1.9	61
411	Alzheimer's disease. <i>Lancet</i> , 2011, 377, 1019-1031.	6.3	2,051
412	Cerebrospinal Fluid Levels of sAPP β and sAPP α in Lewy Body and Alzheimer's Disease: Clinical and Neurochemical Correlates. <i>International Journal of Alzheimer's Disease</i> , 2011, 2011, 1-6.	1.1	19
413	Nonmotor Symptoms of Parkinson's Disease. <i>Parkinson's Disease</i> , 2011, 2011, 1-2.	0.6	1
414	Authors' reply to McShane and Regnard. <i>BMJ: British Medical Journal</i> , 2011, 343, d5356-d5356.	2.4	0

#	ARTICLE	IF	CITATIONS
415	Journal Watch: Our panel of experts highlight the most important research articles across the spectrum of topics relevant to the field of neurodegenerative disease management. <i>Neurodegenerative Disease Management</i> , 2011, 1, 187-189.	1.2	0
416	Mania After Administration of Cholinesterase Inhibitors in Patients With Dementia and Comorbid Bipolar Disorder. <i>Journal of Clinical Psychopharmacology</i> , 2011, 31, 254-256.	0.7	13
417	Verbal memory in drug-naive, newly diagnosed Parkinson's disease. The retrieval deficit hypothesis revisited.. <i>Neuropsychology</i> , 2011, 25, 114-124.	1.0	88
418	Depression in dementia. <i>Current Opinion in Psychiatry</i> , 2011, 24, 461-472.	3.1	259
419	Initial prescription of antipsychotics and antidepressants in general practice and specialist care in Norway. <i>Acta Psychiatrica Scandinavica</i> , 2011, 123, 459-465.	2.2	29
420	Identification of Novel α -Synuclein Isoforms in Human Brain Tissue by using an Online NanoLC-ESI-FTICR-MS Method. <i>Neurochemical Research</i> , 2011, 36, 2029-2042.	1.6	99
421	Mild Cognitive Impairment in Parkinson's Disease. <i>Current Neurology and Neuroscience Reports</i> , 2011, 11, 371-378.	2.0	131
422	Reply: Neuropsychiatric symptoms in Parkinson's disease. <i>Movement Disorders</i> , 2011, 26, 191-192.	2.2	0
423	Nonlinear decline of mini-mental state examination in Parkinson's disease. <i>Movement Disorders</i> , 2011, 26, 334-337.	2.2	40
424	Ventricular enlargement and mild cognitive impairment in early Parkinson's disease. <i>Movement Disorders</i> , 2011, 26, 297-301.	2.2	50
425	Cognitive correlates of visual hallucinations in dementia associated with Parkinson's disease. <i>Movement Disorders</i> , 2011, 26, 824-829.	2.2	32
426	The economic impact of cognitive impairment in Parkinson's disease. <i>Movement Disorders</i> , 2011, 26, 1541-1544.	2.2	100
427	MDS task force on mild cognitive impairment in Parkinson's disease: Critical review of PD-MCI. <i>Movement Disorders</i> , 2011, 26, 1814-1824.	2.2	649
428	Cognitive impairment in nondemented Parkinson's disease. <i>Movement Disorders</i> , 2011, 26, 2483-2495.	2.2	115
429	Efficacy of memantine in PDD and DLB: an extension study including washout and open-label treatment. <i>International Journal of Geriatric Psychiatry</i> , 2011, 26, 206-213.	1.3	20
430	Hypertension is a potential risk factor for vascular dementia: systematic review. <i>International Journal of Geriatric Psychiatry</i> , 2011, 26, 661-669.	1.3	184
431	Depression in mild dementia: associations with diagnosis, APOE genotype and clinical features. <i>International Journal of Geriatric Psychiatry</i> , 2011, 26, 1054-1061.	1.3	36
432	Pain treatment of agitation in patients with dementia: a systematic review. <i>International Journal of Geriatric Psychiatry</i> , 2011, 26, 1012-1018.	1.3	87

#	ARTICLE	IF	CITATIONS
433	The role of pain treatment in managing the behavioural and psychological symptoms of dementia (BPSD). <i>International Journal of Palliative Nursing</i> , 2011, 17, 420-424.	0.2	35
434	Early and Presenting Symptoms of Dementia with Lewy Bodies. <i>Dementia and Geriatric Cognitive Disorders</i> , 2011, 32, 202-208.	0.7	77
435	CSF amyloid A β 38 as a novel diagnostic marker for dementia with Lewy bodies. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2011, 82, 160-164.	0.9	50
436	Depressive Symptoms in Alzheimer's Disease and Lewy Body Dementia: A One-Year Follow-Up Study. <i>Dementia and Geriatric Cognitive Disorders</i> , 2011, 32, 143-149.	0.7	47
437	Atypical antipsychotics for the treatment of behavioral and psychological symptoms in dementia, with a particular focus on longer term outcomes and mortality. <i>Expert Opinion on Drug Safety</i> , 2011, 10, 35-43.	1.0	126
438	Nursing home structure and association with agitation and use of psychotropic drugs in nursing home residents in three countries: Norway, Austria and England. <i>International Journal of Geriatric Psychiatry</i> , 2010, 25, 725-731.	1.3	35
439	Health and well-being in care staff and their relations to organizational and psychosocial factors, care staff and resident factors in nursing homes. <i>International Journal of Geriatric Psychiatry</i> , 2010, 25, 789-797.	1.3	63
440	Effects of Rivastigmine in Alzheimer's Disease Patients with and Without Hallucinations. <i>Journal of Alzheimer's Disease</i> , 2010, 20, 301-311.	1.2	20
441	Rivastigmine for the treatment of Parkinson's disease dementia. <i>Aging Health</i> , 2010, 6, 277-284.	0.3	0
442	Disturbance of automatic auditory change detection in dementia associated with Parkinson's disease: A mismatch negativity study. <i>Neurobiology of Aging</i> , 2010, 31, 104-113.	1.5	56
443	Apathy in drug-naïve patients with incident Parkinson's disease: the Norwegian ParkWest study. <i>Journal of Neurology</i> , 2010, 257, 217-223.	1.8	87
444	The effect of memantine on sleep behaviour in dementia with Lewy bodies and Parkinson's disease dementia. <i>International Journal of Geriatric Psychiatry</i> , 2010, 25, 1030-1038.	1.3	65
445	Hippocampal, caudate, and ventricular changes in Parkinson's disease with and without dementia. <i>Movement Disorders</i> , 2010, 25, 687-695.	2.2	145
446	Gray matter correlations of cognition in incident Parkinson's disease. <i>Movement Disorders</i> , 2010, 25, 629-633.	2.2	61
447	Frequency and Correlates of Caregiver-Reported Sleep Disturbances in a Sample of Persons with Early Dementia. <i>Journal of the American Geriatrics Society</i> , 2010, 58, 480-486.	1.3	112
448	Caregiver distress associated with neuropsychiatric problems in patients with early Parkinson's disease: the Norwegian ParkWest study. <i>Acta Neurologica Scandinavica</i> , 2010, 122, 418-424.	1.0	62
449	The Epidemiology of Dementia Associated with Parkinson's Disease. <i>Brain Pathology</i> , 2010, 20, 633-639.	2.1	253
450	Rivastigmine in the Treatment of Dementia Associated with Parkinson's Disease: Effects on Activities of Daily Living. <i>Dementia and Geriatric Cognitive Disorders</i> , 2010, 29, 510-515.	0.7	23

#	ARTICLE	IF	CITATIONS
451	Evaluating Rivastigmine in Mild-to-Moderate Parkinson's Disease Dementia Using ADAS-Cog Items. <i>American Journal of Alzheimer's Disease and Other Dementias</i> , 2010, 25, 407-413.	0.9	21
452	CSF amyloid- β and tau proteins, and cognitive performance, in early and untreated Parkinson's Disease: the Norwegian ParkWest study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2010, 81, 1080-1086.	0.9	190
453	Core and Suggestive Symptoms of Dementia with Lewy Bodies Cluster in Persons with Mild Dementia. <i>Dementia and Geriatric Cognitive Disorders</i> , 2010, 29, 317-324.	0.7	22
454	A 12-Year Population-Based Study of Psychosis in Parkinson Disease. <i>Archives of Neurology</i> , 2010, 67, 996-1001.	4.9	323
455	Is physical activity a potential preventive factor for vascular dementia? A systematic review. <i>Aging and Mental Health</i> , 2010, 14, 386-395.	1.5	167
456	α -synuclein antibodies recognize a protein present at lower levels in the CSF of patients with dementia with Lewy bodies. <i>International Psychogeriatrics</i> , 2010, 22, 321-327.	0.6	20
457	Biomarkers of PD progression. <i>Neurology</i> , 2010, 75, 1036-1037.	1.5	4
458	The epidemiology of dementia associated with Parkinson disease. <i>Journal of the Neurological Sciences</i> , 2010, 289, 18-22.	0.3	384
459	Use of drugs with anticholinergic effect and impact on cognition in Parkinson's disease: a cohort study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2010, 81, 160-165.	0.9	187
460	The Effect of Staff Training on Agitation and Use of Restraint in Nursing Home Residents With Dementia. <i>Journal of Clinical Psychiatry</i> , 2010, 71, 80-86.	1.1	72
461	Parkinson's disease dementia and dementia with Lewy bodies: different aspects of one entity. <i>International Psychogeriatrics</i> , 2009, 21, 216.	0.6	61
462	High Prevalence of Orthostatic Hypotension in Mild Dementia. <i>Dementia and Geriatric Cognitive Disorders</i> , 2009, 28, 307-313.	0.7	53
463	APOE Alleles in Parkinson Disease and Their Relationship to Cognitive Decline: A Population-based, Longitudinal Study. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2009, 22, 166-170.	1.2	51
464	Person-centred care and care mapping in dementia. <i>Lancet Neurology</i> , The, 2009, 8, 302-303.	4.9	11
465	Neuropsychiatric symptoms in Parkinson's disease. <i>Movement Disorders</i> , 2009, 24, 2175-2186.	2.2	471
466	Memantine in patients with Parkinson's disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trial. <i>Lancet Neurology</i> , The, 2009, 8, 613-618.	4.9	420
467	Prevalence and clinical correlates of apathy in Parkinson's disease: A community-based study. <i>Parkinsonism and Related Disorders</i> , 2009, 15, 295-299.	1.1	146
468	The association between motor subtypes and psychopathology in Parkinson's disease. <i>Parkinsonism and Related Disorders</i> , 2009, 15, 379-382.	1.1	181

#	ARTICLE	IF	CITATIONS
469	Dopamine-induced proliferation of adult neural precursor cells in the mammalian subventricular zone is mediated through EGF. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 8754-8759.	3.3	181
470	White matter hyperintensities do not impact cognitive function in patients with newly diagnosed Parkinson's disease. NeuroImage, 2009, 47, 2083-2089.	2.1	65
471	CSF Biomarkers and Incipient Alzheimer Disease in Patients With Mild Cognitive Impairment. JAMA - Journal of the American Medical Association, 2009, 302, 385.	3.8	1,009
472	Pain and Its Relationship to Depression in Parkinson Disease. American Journal of Geriatric Psychiatry, 2009, 17, 269-275.	0.6	79
473	Parkinson Disease With Dementia. Alzheimer Disease and Associated Disorders, 2009, 23, 295-297.	0.6	183
474	Pharmacological management of neuropsychiatric symptoms in people with dementia. , 2009, , 105-116.		0
475	A systematic review of prevalence studies of depression in Parkinson's disease. Movement Disorders, 2008, 23, 183-189.	2.2	982
476	Scales to assess psychosis in Parkinson's disease: Critique and recommendations. Movement Disorders, 2008, 23, 484-500.	2.2	172
477	Stopping antipsychotic drug therapy in demented nursing home patients: a randomized, placebo-controlled studyâ€”The Bergen District Nursing Home Study (BEDNURS). International Journal of Geriatric Psychiatry, 2008, 23, 889-895.	1.3	73
478	Neuropsychiatric Correlates of Cerebrospinal Fluid Biomarkers in Alzheimerâ€™s Disease. Dementia and Geriatric Cognitive Disorders, 2008, 25, 559-563.	0.7	54
479	Diagnosis and management of Parkinsonâ€™s disease dementia. International Journal of Clinical Practice, 2008, 62, 1581-1587.	0.8	77
480	Frequency and Case Identification of Dementia with Lewy Bodies Using the Revised Consensus Criteria. Dementia and Geriatric Cognitive Disorders, 2008, 26, 445-452.	0.7	170
481	Validation of the Unified Parkinson's Disease Rating Scale (UPDRS) section I as a screening and diagnostic instrument for apathy in patients with Parkinson's disease. Parkinsonism and Related Disorders, 2008, 14, 183-186.	1.1	34
482	Grey matter atrophy in early versus late dementia in Parkinson's disease. Parkinsonism and Related Disorders, 2008, 14, 620-625.	1.1	18
483	Who Suffers Most? Dementia and Pain in Nursing Home Patients: A Cross-sectional Study. Journal of the American Medical Directors Association, 2008, 9, 427-433.	1.2	135
484	Clinical aspects of Parkinson dementia. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2008, 89, 303-306.	1.0	1
485	Early Discriminatory Diagnosis of Dementia with Lewy Bodies. Dementia and Geriatric Cognitive Disorders, 2008, 25, 195-205.	0.7	40
486	Relationship of cognitive impairment to psychiatric symptoms in multiple sclerosis. Multiple Sclerosis Journal, 2008, 14, 1084-1090.	1.4	36

#	ARTICLE	IF	CITATIONS
487	Cortical Serotonin 1A Receptor Levels Are Associated with Depression in Patients with Dementia with Lewy Bodies and Parkinson's Disease Dementia. <i>Dementia and Geriatric Cognitive Disorders</i> , 2008, 26, 330-338.	0.7	48
488	Dementia in Parkinson's disease. <i>Current Opinion in Neurology</i> , 2008, 21, 676-682.	1.8	76
489	Are anxiety disorders undertreated in patients with multiple sclerosis?. <i>Nature Clinical Practice Neurology</i> , 2007, 3, 372-373.	2.7	6
490	Profile of cognitive impairment in dementia associated with Parkinson's disease compared with Alzheimer's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2007, 78, 1064-1068.	0.9	81
491	FMR1 Alleles in Parkinson's Disease: Relation to Cognitive Decline and Hallucinations, A Longitudinal Study. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2007, 20, 89-92.	1.2	34
492	Gray matter atrophy in Parkinson disease with dementia and dementia with Lewy bodies. <i>Neurology</i> , 2007, 69, 747-754.	1.5	152
493	Caregiver burden in multiple sclerosis: the impact of neuropsychiatric symptoms. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2007, 78, 1097-1102.	0.9	134
494	Subthreshold depression in patients with Parkinson's disease and dementia—clinical and demographic correlates. <i>International Journal of Geriatric Psychiatry</i> , 2007, 22, 980-985.	1.3	18
495	Diagnostic criteria for psychosis in Parkinson's disease: Report of an NINDS, NIMH work group. <i>Movement Disorders</i> , 2007, 22, 1061-1068.	2.2	474
496	Clinical diagnostic criteria for dementia associated with Parkinson's disease. <i>Movement Disorders</i> , 2007, 22, 1689-1707.	2.2	2,497
497	Diagnostic procedures for Parkinson's disease dementia: Recommendations from the movement disorder society task force. <i>Movement Disorders</i> , 2007, 22, 2314-2324.	2.2	885
498	Loss of Musashi1 in Lewy body dementia associated with cholinergic deficit. <i>Neuropathology and Applied Neurobiology</i> , 2007, 33, 070615220219002-???	1.8	10
499	The effect of age of onset of PD on risk of dementia. <i>Journal of Neurology</i> , 2007, 254, 38-45.	1.8	141
500	Management of Parkinson's Disease Dementia. <i>Drugs and Aging</i> , 2006, 23, 807-822.	1.3	19
501	Rivastigmine in Parkinson's Disease Dementia. <i>CNS Drugs</i> , 2006, 20, 748-750.	2.7	1
502	Lewy body disease: Thalamic cholinergic activity related to dementia and parkinsonism. <i>Neurobiology of Aging</i> , 2006, 27, 433-438.	1.5	58
503	Selective nicotinic acetylcholine receptor subunit deficits identified in Alzheimer's disease, Parkinson's disease and dementia with Lewy bodies by immunoprecipitation. <i>Neurobiology of Disease</i> , 2006, 23, 481-489.	2.1	105
504	Depressive symptom profile in Parkinson's disease: a comparison with depression in elderly patients without Parkinson's disease. <i>International Journal of Geriatric Psychiatry</i> , 2006, 21, 252-258.	1.3	98

#	ARTICLE	IF	CITATIONS
505	Visual rating of white matter hyperintensities in Parkinson's disease. <i>Movement Disorders</i> , 2006, 21, 223-229.	2.2	97
506	Cognitive profiles of individual patients with Parkinson's disease and dementia: Comparison with dementia with lewy bodies and Alzheimer's disease. <i>Movement Disorders</i> , 2006, 21, 337-342.	2.2	103
507	Changes in motor subtype and risk for incident dementia in Parkinson's disease. <i>Movement Disorders</i> , 2006, 21, 1123-1130.	2.2	374
508	Subtypes of mild cognitive impairment in parkinson's disease: Progression to dementia. <i>Movement Disorders</i> , 2006, 21, 1343-1349.	2.2	541
509	Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson's disease. <i>Movement Disorders</i> , 2006, 21, 1899-1907.	2.2	290
510	Associations between family history of Parkinson's disease and dementia and risk of dementia in Parkinson's disease: A community-based, longitudinal study. <i>Movement Disorders</i> , 2006, 21, 2170-2174.	2.2	22
511	A magnetic resonance imaging study of patients with Parkinson's disease with mild cognitive impairment and dementia using voxel-based morphometry. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2006, 78, 254-259.	0.9	235
512	Familial Occurrence of Dementia and Parkinsonism. <i>Dementia and Geriatric Cognitive Disorders</i> , 2006, 22, 288-295.	0.7	22
513	Current perspectives in dementia with Lewy bodies. <i>Aging Health</i> , 2006, 2, 461-472.	0.3	1
514	Psychiatric aspects of Parkinson's disease. <i>Current Opinion in Psychiatry</i> , 2005, 18, 335-341.	3.1	12
515	The influence of cerebrovascular risk factors on incident dementia in patients with Parkinson's disease. <i>Acta Neurologica Scandinavica</i> , 2005, 112, 386-390.	1.0	53
516	Neuropsychiatric disturbances in Parkinson's disease clusters in five groups with different prevalence of dementia. <i>Acta Psychiatrica Scandinavica</i> , 2005, 112, 201-207.	2.2	70
517	Neuropsychiatric symptoms in patients with multiple sclerosis. <i>Acta Psychiatrica Scandinavica</i> , 2005, 112, 463-468.	2.2	87
518	The effect of staff training on the use of restraint in dementia: a single-blind randomised controlled trial. <i>International Journal of Geriatric Psychiatry</i> , 2005, 20, 587-590.	1.3	107
519	Neuropathology of dementia in Parkinson's disease: A prospective, community-based study. <i>Annals of Neurology</i> , 2005, 58, 773-776.	2.8	312
520	A systematic review of prevalence studies of dementia in Parkinson's disease. <i>Movement Disorders</i> , 2005, 20, 1255-1263.	2.2	1,060
521	Psychiatric and behavioral symptoms in Alzheimer's disease and other dementias: Etiology and management. <i>Current Neurology and Neuroscience Reports</i> , 2005, 5, 345-354.	2.0	23
522	Role of Neuropsychiatric Assessment in Diagnosis and Research. , 2005, , 163-183.		0

#	ARTICLE	IF	CITATIONS
523	Progression of motor impairment and disability in Parkinson disease. <i>Neurology</i> , 2005, 65, 1436-1441.	1.5	224
524	Cognitive Predictors of Dementia in Parkinson's Disease: A Community-Based, 4-Year Longitudinal Study. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2005, 18, 149-154.	1.2	158
525	Neuroleptic Sensitivity in Parkinson's Disease and Parkinsonian Dementias. <i>Journal of Clinical Psychiatry</i> , 2005, 66, 504-514.	1.1	178
526	Cognitive impairment and dementia in Parkinson's disease. , 2005, , 657-663.		0
527	Neuroleptic sensitivity in Parkinson's disease and parkinsonian dementias. <i>Journal of Clinical Psychiatry</i> , 2005, 66, 633-7.	1.1	72
528	Disorders of motivation, sexual conduct, and sleep in Parkinson's disease. <i>Advances in Neurology</i> , 2005, 96, 56-64.	0.8	18
529	Role of Cholinesterase Inhibitors in Parkinson's Disease and dementia with Lewy Bodies. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2004, 17, 164-171.	1.2	149
530	Dopamine Transporter Loss Visualized With FP-CIT SPECT in the Differential Diagnosis of Dementia With Lewy Bodies. <i>Archives of Neurology</i> , 2004, 61, 919.	4.9	312
531	Psychiatric Aspects of Parkinson's Disease, Parkinson's Disease with Dementia, and Dementia with Lewy Bodies. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2004, 17, 111-111.	1.2	3
532	Are Parkinson's Disease with dementia and Dementia with lewy Bodies the Same Entity?. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2004, 17, 137-145.	1.2	180
533	Improvement in behavioral symptoms and advance of activity acrophase after short-term bright light treatment in severe dementia. <i>Psychiatry and Clinical Neurosciences</i> , 2004, 58, 343-347.	1.0	81
534	Dementia with Lewy bodies. <i>Lancet Neurology</i> , The, 2004, 3, 19-28.	4.9	645
535	Psychiatric issues in non-Alzheimer dementias. <i>Clinical Neuroscience Research</i> , 2004, 3, 397-412.	0.8	6
536	A multinational, randomised, 12-week study comparing the effects of donepezil and galantamine in patients with mild to moderate Alzheimer's disease. <i>International Journal of Geriatric Psychiatry</i> , 2004, 19, 58-67.	1.3	102
537	Pentagon drawing and neuropsychological performance in Dementia with Lewy Bodies, Alzheimer's disease, Parkinson's disease and Parkinson's disease with dementia. <i>International Journal of Geriatric Psychiatry</i> , 2004, 19, 371-377.	1.3	119
538	Psychiatric issues in non-Alzheimer dementias. <i>Clinical Neuroscience Research</i> , 2004, 3, 397-397.	0.8	1
539	Rivastigmine for Dementia Associated with Parkinson's Disease. <i>New England Journal of Medicine</i> , 2004, 351, 2509-2518.	13.9	1,111
540	The Rate of Cognitive Decline in Parkinson Disease. <i>Archives of Neurology</i> , 2004, 61, 1906-11.	4.9	222

#	ARTICLE	IF	CITATIONS
541	Cognitive, psychiatric and motor response to galantamine in Parkinson's disease with dementia. <i>International Journal of Geriatric Psychiatry</i> , 2003, 18, 937-941.	1.3	197
542	Familial Parkinson's disease: a community-based study. <i>European Journal of Neurology</i> , 2003, 10, 159-163.	1.7	28
543	Neuropsychological Profile of Patients with Parkinson's Disease without Dementia. <i>Dementia and Geriatric Cognitive Disorders</i> , 2003, 15, 126-131.	0.7	183
544	Prevalence and Characteristics of Dementia in Parkinson Disease. <i>Archives of Neurology</i> , 2003, 60, 387.	4.9	1,285
545	Basal ganglia diseases and geriatric psychiatry: a new approach. <i>Current Opinion in Psychiatry</i> , 2003, 16, 621-627.	3.1	1
546	The psychosocial burden on spouses of the elderly with stroke, dementia and Parkinson's disease. <i>International Journal of Geriatric Psychiatry</i> , 2002, 17, 78-84.	1.3	201
547	Depression in Parkinson's disease. <i>Acta Psychiatrica Scandinavica</i> , 2002, 106, 161-162.	2.2	13
548	Neuropsychiatric Symptoms of Patients With Progressive Supranuclear Palsy and Parkinson's Disease. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2001, 13, 42-49.	0.9	149
549	Comparison of Extrapyrarnidal Signs in Dementia With Lewy Bodies and Parkinson's Disease. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2001, 13, 374-379.	0.9	71
550	A comparative study of psychiatric symptoms in dementia with Lewy bodies and Parkinson's disease with and without dementia. <i>International Journal of Geriatric Psychiatry</i> , 2001, 16, 528-536.	1.3	321
551	Neuropsychiatric differences between Parkinson's disease with dementia and Alzheimer's disease. <i>International Journal of Geriatric Psychiatry</i> , 2001, 16, 184-191.	1.3	140
552	Predictors of Nursing Home Placement in Parkinson's Disease: A Population-Based, Prospective Study. <i>Journal of the American Geriatrics Society</i> , 2000, 48, 938-942.	1.3	658
553	Prevalence and Clinical Correlates of Psychotic Symptoms in Parkinson Disease. <i>Archives of Neurology</i> , 1999, 56, 595.	4.9	363
554	Neuropsychiatric aspects of parkinson's disease. <i>Current Psychiatry Reports</i> , 1999, 1, 61-68.	2.1	57
555	Donepezil for dementia with Lewy bodies: a case study. , 1999, 14, 69-72.		60
556	Lexical and Nonlexical Spelling Deficits in Dementia of the Alzheimer Type. <i>Brain and Language</i> , 1996, 52, 551-563.	0.8	18
557	Man with fluctuating confusion. , 0, , 148-154.		0
558	Parkinson's disease: pathology, anatomy, and behavior. , 0, , 14-24.		0

#	ARTICLE	IF	CITATIONS
559	The boundaries of Parkinson's disease dementia and dementia with Lewy bodies. , 0, , 40-52.		0
560	Clinical assessment: mood and motivation. , 0, , 65-72.		0
561	Imaging and behavior in Parkinson's disease: structural imaging. , 0, , 73-88.		0
562	Imaging and behavior in Parkinson's disease: functional imaging. , 0, , 89-96.		0
563	Diagnosis and biomarkers: CSF. , 0, , 97-108.		0
564	Apathy. , 0, , 131-139.		0
565	Early cognitive impairment. , 0, , 163-176.		1
566	Parkinson's disease dementia. , 0, , 177-191.		0
567	Sleep disturbances. , 0, , 192-210.		0
568	Surgical treatment and behavior. , 0, , 230-243.		0
569	Clinical trials for psychotropic agents in Parkinson's disease using psychosis as a model. , 0, , 244-254.		0
570	Treatment of neuropsychiatric disturbances in Parkinson's disease: future prospects and strategies. , 0, , 285-291.		0
571	The genetics of behavior and cognition in Parkinson's disease. , 0, , 25-39.		0